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The immunological synapse (IS) is a dynamic structure formed between 
lymphocytes and antigen presenting cells. Previous work has shown that 
enhancing PI3K signaling by depletion of the lipid phosphatase PTEN 
increases the size of the IS.  In addition, cytotoxic T lymphocytes (CTLs) 
lacking PTEN exhibit increased killing capacity in vitro. We discovered that 
CTL force exertion across the IS is coordinated with the release of the toxic 
proteins perforin and granzyme and is correlated with specific lysis of target 
cells. We connected these two observations and proposed a model in which T 
cells use mechanical force at the IS to alter the tension of the target cell 
plasma membrane, increasing target cell susceptibility to perforin. Adoptive T 
cell therapies have shown the potential to transform the treatment of some 
forms of cancer and are of great interest to clinicians. We hypothesized that 
increasing the killing efficacy of the transferred T cells would increase the 
effectiveness of these treatments. Accordingly, we assessed the potential of 
PTEN deficiency to boost anti-cancer responses in a subcutaneous 
transplantable tumor model. We found that depletion of PTEN in CTLs 
resulted in reduced tumor rejection relative to wild type control CTLs.  Our 
work indicated that this decrease in tumor rejection stemmed from reduced 
persistence of PTEN deficient CTLs in vivo. We examined the contributions to 
persistence from migration, survival, and homeostatic proliferation. We found 
that PTEN deficient CTLs have reduced migration and homeostatic 
proliferation, which results in diminished persistence in vivo. Our work 
  
highlights the importance of migration and homeostatic proliferation in 
developing an anti-tumor response.  
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CHAPTER 1: INTRODUCTION 
1.1. Innate and adaptive immunity 
Animals have evolved an immune system to protect against foreign 
pathogens. The immune system is divided into two branches, which work 
together to establish host immunity. The first arm of the immune system is the 
innate immune system, which provides an initial defense against pathogens 
and can be triggered very quickly but is limited in the scope of molecules it 
recognizes. The second arm is the adaptive immune system, which is slower 
to establish a response but can tailor that response to a specific antigen. 
Innate immune cells have pattern recognition receptors that identify foreign 
cells and proteins. These cells are important for presenting foreign molecules 
to cells in the adaptive immune system. 
The adaptive immune system is made up of B cells and T cells. The 
primary role of B cells is to produce antibodies. These antibodies bind to 
molecules and identify them as foreign to other immune cells. There are two 
main subtypes of T cells, CD4+ and CD8+ T cells, which are named for the co-
receptor the cells express. These subtypes have very distinct roles in driving 
host immunity. CD4+ T cells differentiate into T-helper cells and CD8+ T cells 
differentiate into cytotoxic T lymphocytes (CTLs). CTLs are capable of killing 
malignant or infected cells in addition to producing inflammatory cytokines 
such as interleukin-2 (IL-2), interferon gamma (IFNγ), and tumor necrosis 
factor alpha (TNFα)1. 
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1.2. T cells 
T cells are defined by expression of the T cell receptor (TCR). The TCR 
is a multisubunit receptor consisting of α-, β-, γ-, δ-, ε-, and ζ-chains. These 
subunits form a complex that recognizes an antigenic peptide in the major 
histocompatibility complex (MHC) on an antigen-presenting cell (APC). There 
are two categories of MHC molecules, which are called class I and class II 
(referred to as MHC I and MHC II, respectively). The specificity of an αβ T cell 
for MHC I or MHC II is determined by the co-receptor it expresses. CD8+ T 
cells recognize peptides presented by MHC I and CD4+ T cells recognize 
peptides presented by MHC II. 
T cell development is a tightly regulated process that has been carefully 
delineated. T cells differentiate from thymic progenitors that originate in the 
bone marrow2. In the thymus, these cells go through several stages of 
differentiation to become T cells. T cells undergo programmed rearrangement 
of the β chain of the TCR to increase diversity of the TCRs2. During this 
process, some TCRs become non-functional and unable to recognize pMHC 
complexes. These cells undergo programmed cell death during beta 
selection2. Next, cells undergo rearrangements of their α chain and 
subsequent positive selection2. The surviving cells then go through negative 
selection. This removes T cells with receptors that bind with high affinity to 
MHC complexes containing host peptides2. Negative selection ensures that T 
cells are removed if they express a TCR that would generate auto-immunity. 
This process is not completely efficient and some self-reactive T cells survive 
negative selection. Some of these T cells will differentiate into regulatory T 
cells (Tregs), which play a crucial role in immune tolerance3. After all of these 
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checkpoints, naïve T cells leave the thymus where they begin the process of 
surveying the host looking for infected or malignant cells. 
1.2.1. T cell signaling 
Following the formation of a TCR-pMHC interaction and recognition of 
an antigenic peptide, many downstream signaling pathways are activated. 
These signaling events trigger rapid changes in T cell morphology and 
function. TCR signaling begins with lymphocyte-specific protein tyrosine 
kinase (Lck), a Src family kinase, phosphorylating the immunoreceptor 
tyrosine-based activation motifs (ITAMs) on the TCR4. ITAMs are signaling 
motifs contained within the cytoplasmic tails of the CD3 γ-, δ-, ε-, and ζ-
chains5. Phosphorylated ITAMs recruit the tyrosine kinase zeta-chain-
associated protein kinase 70 (ZAP70) to the TCR, where it phosphorylates the 
scaffolding proteins linker for activation of T cells (LAT) and lymphocyte 
cytosolic protein 2 (SLP76), inducing them to form a complex. This LAT-
SLP76 complex then recruits various downstream signaling proteins including 
phospholipase gamma (PLCγ), which produces diacylglycerol (DAG) and 
inositol 1,4,5-trisphosphate (IP3).  IP3 signaling drives an increase in the level 
of intracellular calcium (Ca2+), which results in nuclear factor of activated T 
cells (NFAT) localizing to the nucleus. DAG, in turn allows RAS guanyl-
releasing protein 1 (RASGRP1) to be activated leading to the activation of Ras 
and downstream signaling proteins including mitogen-activated protein kinase 
(ERK) and mitogen-activated protein kinase kinase (MEK). DAG also induces 
nuclear factor kappa-light-chain-enhancer of activated B cells (NFκB) signaling 
through protein kinase C theta (PKCθ)6. Following these stages of activation, 
T cells upregulate activation markers such as CD69 and secrete cytokines 
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including but not limited to IL-2, IFNγ, and TNFα. These pro-inflammatory 
cytokines help coordinate an immune response among many cell types. 
Activation of RAS also leads to the activation of the 
phosphatidylinositol-4,5-bisphosphate 3-kinase (PI3K) signaling pathway 
(Figure 1.1). In the first part of the pathway, PI3K phosphorylates the lipid 
phosphatidylinositol-4,5-bisphosphate (PIP2), generating phosphatidylinositol-
3,4,5-trisphosphate (PIP3)7. Phosphatase and tensin homolog (PTEN) 
attenuates PI3K signaling by dephosphorylating PIP3 to yield PIP2. PIP3 binds 
to and recruits protein kinase B (AKT), localizing it to the plasma membrane 
and allowing it to be phosphorylated by the regulatory Ser/Thr kinase 
phosphoinositide-dependent kinase-1 (PDK1). Once phosphorylated, AKT 
activates a number of pathways controlling cell growth and proliferation. In 
another arm of the PI3K signaling pathway, PIP3 recruits the guanine 
nucleotide exchange factor (GEF) dedicator of cytokinesis 2 (Dock2) to the 
plasma membrane8. This branch of the pathway will be discussed below. 
 AKT signaling acts through a number of downstream proteins including 
the mammalian target of rapamycin (mTOR)7. mTOR is a complex of several 
proteins and has two main components named complex 1 and complex 2 
(mTORC1 and mTORC2 respectively). mTORC2 has been found to activate 
AKT, which in turn signals through mTORC19. These complexes play an 
important role in nutrient sensing and cell growth. AKT also regulates forkhead 
box protein O1 (FOXO1), which is responsible for controlling expression 
interleukin-7 receptor alpha (IL-7Rα)10,11. An increase in AKT signaling 
increases mTORC1 and reduces FOXO1 signaling, which reduces expression 
of the transcription factor Krüppel-like Factor 2 (KLF2). KLF2 is responsible for  
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Figure 1.1 Cartoon of the PI3K signaling pathway 
T cell activation through TCR and LFA-1 results in the phosphorylation of PIP2 
to PIP3 by PI3K. PIP3 accumulation results in several down stream signaling 
processes. PIP3 recruits AKT to the plasma membrane, which results in its 
phosphorylation by PDK1. mTORC2 signals through AKT and increases AKT 
signaling. AKT phosphorylates FOXO1, which prevents it from localizing to the 
nucleus and reduces expression of IL-7Rα. AKT also activates mTORC1 and 
the scaffold Raptor. Increased mTORC1 signaling has been shown to reduce 
KLF2 expression, which reduces expression of S1PR1, CCR7, and CD62L. 
PIP3 also recruits Dock2 and its scaffold Elmo to the plasma membrane. Elmo 
allows Rac/Rho small GTPases to bind and signals through WAVE complex to 
Arp2/3 to control actin growth. 
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regulating the expression C-C chemokine receptor type 7 (CCR7), L-selectin 
(CD62L), and sphingosine-1-phosphate receptor 1 (S1PR1), which are 
important regulators of T cell trafficking that will be discussed below.  
1.2.2. Immunological synapse 
Upon binding of the TCR to pMHC on an APC, T cells undergo 
dramatic changes in their cytoskeleton creating a structurally stereotyped 
interface with the APC. This interaction, called the immunological synapse (IS) 
is an annular structure that resembles a “bulls-eye” with a ring of actin making 
up the perimeter (Figure 1.2). The IS has been shown to be important for the 
targeted release of some cytokines and lytic granules (LG)13,14. 
Following TCR activation, actin polymerization occurs rapidly forming 
the IS. Previous work has demonstrated that the formation of this annular actin 
structure depends on PIP3 accumulation following TCR activation8. PIP3 
recruits the GEF Dock2, which induces the activation of the Rho family 
Figure 1.2 Cartoon of the IS between a T cell and an APC 
(A) A diagram of a T cell forming a conjugate with an APC. The IS is depicted 
as a “bulls-eye” structure on the interface. (B) The IS is divided into the 
dSMAC, pSMAC, and cSMAC. During the formation and maturation of the IS, 
various proteins are segregated into the different regions. This figure was 
adapted from Yu, Y. et al.12. 
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GTPase Rac. Activated Rac then signals through the Wiskott-Aldrich 
syndrome protein family member 2 (WAVE2) to facilitate lamellipodial 
growth8,15. Rac does not interact with WAVE2 directly but interacts with the 
WAVE complex containing WAVE2, Sra, Nap, and Brk115. WAVE2 then 
promotes lamellipodial growth through the Arp2/3 protein complex. Arp2/3 
initiates the formation of y-branches of actin at the lamellipodia16,17. The 
observation that PIP3 controls actin dynamics by signaling through Dock2 and 
Rho/Rac to Arp2/3 does not rule out the possibility that PIP3 could signal 
through other molecules that have not been identified. 
Segregation of proteins into different regions of the IS called the central, 
peripheral, and distal supramolecular activation cluster  (cSMAC, pSMAC, 
and dSMAC respectively) has been observed in mature T cell-APC 
synapses18. The cSMAC, which is located at the center of the IS, contains the 
TCR, CD28, and PKCθ18,19. The pSMAC, which surrounds the cSMAC, 
contains lymphocyte function-associated antigen 1 (LFA-1) and Talin18. CD45 
is initially localized to the pSMAC, but is then gradually excluded based on the 
size of its large ectodomain20. The dSMAC surrounds the pSMAC in the 
mature IS and contains the F-actin ring and CD45.  CD43 was also found to 
localize to the dSMAC21. Most of the work characterizing the migration of 
proteins to the different regions of the IS has been performed on lipid bilayers 
containing stimulatory ligands. In these experiments, T cells form a single IS 
that resembles a “bulls-eye.” However, the direct implications of this work are 
unclear as synapses T cell-APC conjugates have been shown to form multiple 
regions resembling the cSMAC19,22. Thus, lipid bilayers are not able to fully 
recapitulate a proper T cell-APC conjugate. More research utilizing high-
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resolution microscopy is needed to examine the precise structure of the T cell-
APC IS and to understand its function. 
1.2.3. T cell motility 
Actin plays a very important role in T cell motility. It allows T cells to 
migrate through lymphoid organs and the periphery. As T cell move, they 
develop the classical “hand-mirror” morphology with a leading edge or 
lamellipodia, consisting of highly branched actin23. Lymphocyte motility is 
driven by the formation of a branched network of actin through the actin 
related protein-2/-3 complex (Arp2/3), which facilitates actin nucleation 
events17. These nucleation events occur at 70° making a y-shape branch17. 
This process is highly regulated by members of the WAVE and Wiskott–
Aldrich syndrome protein (WASP) protein families, which were previously 
described. The lamellipodial protrusions containing branched actin are also 
involved in scanning the environment for antigens. Following antigen 
recognition, the motility of the T cell is reduced and the migration of T cells is 
halted. This stop signal has been found to be calcium dependent24. 
1.2.4. T cell migration 
T cell homing and migration are complex processes that combine 
chemokine signaling, integrins, and adhesion receptors. Naïve T cells circulate 
among lymph nodes through lymphatic vessels and blood25. T cells use 
CD62L to roll on high endothelial venules (HEVs) and to resist hemodynamic 
flow (Figure 1.3). Upon activation, T cells shed CD62L by cleavage with matrix 
metalloproteinase (MMPs)26. CD62L recognizes mucin like glycoproteins 
called peripheral node addressin (PNAd). These proteins include which 
include CD34, podocalyxin, endomucin, nepmucin, and glycosylation- 
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dependent cell adhesion molecule 1, and endothelial-expressed P-selectin 
glycoprotein ligand 125,28. T cells rolling on HEVs express CCR7 and thus 
respond to the C-C motif chemokine ligand 19 and 21 (CCL19 and CCL21 
respectively). These chemokines are produced by the endothelial cells on 
HEVs29. These signals upregulate LFA-1 on the T cells resulting in increased 
adhesion to the HEVs, which express LFA-1’s binding partner intercellular 
adhesion molecule 1 (ICAM-1)29. Thus begins the extravasation process 
whereby T cells leave the circulatory system through the HEVs and enter the 
lymph node25,28. T cells extravasate from the blood into the paracortex of 
lymph nodes. Here naïve T cells scan dendritic cells in search of their cognate 
peptide. If antigens are not detected, T cells will migrate to another lymph 
node through the lymphatic vessels after 6-12 hours28,30. Memory T cells 
reside close to HEVs, which positions them in a good location for encountering 
APCs cells traveling through the lymphatics31. In the paracortex, naïve T cells 
upregulate S1P1R1, which is the receptor that recognizes sphingosine-1-
Figure 1.3 T cell migration on HEVs 
T cells migrate through the circulatory system by rolling on HEVs. Rolling is 
facilitated by CD62L binding to molecules on the HEVs including PNAd. 
Epithelial cells secrete CCL19 and CCL21, which upregulate LFA-1 on the T 
cell. LFA-1 on the T cell surface binds to ICAM-1 on the epithelial cells and 
stops the T cell from rolling. T cells begin extravasating in between the 
epithelial cells. During this process, MMPs cleave CD62L on the T cells. This 
figure was adapted from Lewis, M. et al.27. 
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phosphate (S1P)25. Experiments utilizing pertussis toxin (an inhibitor of G-
protein coupled receptors) and the small molecule FTY720, which induces 
S1P1R1 downregulation, have demonstrated the importance of S1P signaling 
in maintaining T cells in the lymph node32,33. When S1P signaling is blocked 
with either of these agents, lymphocytes are unable to egress and, as a result, 
accumulate in the lymph nodes.  
The migration of T cells towards APCs expressing their cognate antigen 
is two sided as APCs also migrate in search of T cells. When a dendritic cell is 
primed in the periphery, it matures, upregulating CCR7 and traveling through 
lymphatics to the draining lymph node where it comes into contact with T cells. 
In lymph nodes, a single APC is capable of scanning at least 500 T cells per 
hour34. This suggests that in an hour 200 APCs are sufficient to identify a 
single antigen specific T cell in 105 cells34. Over several days, T cells are 
capable of scanning orders of magnitude more APCs. An important 
consideration in these calculations is that scanning cannot occur too fast or 
the T cell will be unable to properly recognize its cognate antigen. As a result, 
T cells balance their ability to scan a wide variety of cells quickly with the need 
to spend enough time on each contact to allow the T cell to become 
activated35.  
This scanning process is enabled by several characteristics of T cell 
signaling. This process is aided by the fact that TCRs are highly sensitive and 
a T cell is capable of recognizing a single pMHC molecule in vitro36. T cell 
signaling has been shown to be digital in nature37. These characteristics allow 
T cells to scan a large number of antigens while maintaining their high 
specificity for their cognate peptide. The process of naïve T cell migration 
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through secondary lymphoid organs has been characterized as a random 
walk38. This differs from the migration pattern of effector or memory T cells, 
which undergo chemotaxis towards an area of injury or inflammation39.  
As cancerous cells proliferate and establish a tumor, these cells require 
additional nutrients. To resolve this problem, tumors undergo angiogenesis to 
generate their own vasculature. This increases the ability of lymphocytes to 
infiltrate tumors. One way that tumors evade detection by the immune system 
is to evolve ways of preventing lymphocyte extravasation from blood. They 
achieve this by down-regulating ICAM-1 and other integrins40. As a solid tumor 
grows, the environment in its interior becomes hostile for lymphocytes40. This 
results in tumor infiltrating lymphocytes dying and becoming dysfunctional41,42. 
How to increase lymphocyte migration to tumors and to prevent or reverse 
their dysfunction is an active area of research. 
T cells that migrate to the tumor and survive its inhospitable 
environment are exposed to a number of signals to reduce their activity.  
Parallels have been drawn between dysfunctional T cells found in solid tumors 
and T cell exhaustion that occurs from chronic infections such as HIV41,43. T 
cells in mice infected with lymphocytic choriomeningitis virus (LCMV) clone 13 
become exhausted and have reduced proliferation and cytokine production 
upon restimulation42,44,45. These cells express high levels of the inhibitory 
receptor programmed cell death protein 1 (PD-1). This is thought to occur in 
response to chronic antigen stimulation through the TCR and perpetual 
exposure to an inflammatory environment42. It is conceivable that reversal of 
this dysfunctional phenotype would result in an increased immune response 
against the infection or cancer. Thus, this is an active area of research. Some 
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approaches that are thought to reverse the tolerogenic environment of the 
tumor will be discussed below. 
1.2.5. Apoptosis 
The ability of cells to undergo programmed cell death is critical for 
homeostasis. The acquired ability of cells to evade apoptosis and to become 
resistant to programmed cell death is one of the hallmarks of cancer46. The 
process of undergoing apoptosis is tightly regulated with many checkpoints to 
ensure that it does not happen unintentionally. 
One way cells undergo apoptosis is in response to Fas signaling, which 
is initiated after trimeric FasL engages trimeric Fas (Figure 1.4)47. Binding of 
Fas ligand (FasL) exposes the death domain (DD) protein motif on the 
intracellular tail of Fas47. This results in the recruitment of Fas associated 
death domain (FADD), which in turn recruits pro-caspase-8 to the receptor. 
Pro-caspase-8 is then cleaved into its active form of caspase-8. The next step 
varies between cell types, which undergo either Type I or Type II apoptosis. In 
Type I cells, caspase-8 directly cleaves pro-caspase-3 to caspase-3, and 
induces cell death. In Type II cells, caspase-8 cleaves BH3 interacting-domain 
death agonist (BID) into truncated BID (tBID). In healthy cells, BID is located 
on the mitochondrial membrane and is a pro-apoptotic member of the B-cell 
lymphoma 2 (Bcl-2) family of proteins. tBID interacts with Bcl-2 associated X 
(Bax) and Bcl-2 antagonist/killer 1 (Bak), triggering their insertion into the 
mitochondrial membrane, which permeabilizes it. In cells that do not undergo 
apoptosis, pro-survival Bcl-2 family proteins sequester Bax and Bak on the 
mitochondrial surface and prevent them from puncturing the mitochondrial 
membrane48. These pro-survival proteins include Bcl-2, BCL2 Like 1 (Bcl-XL),  
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Figure 1.4 Cartoon of Fas induced apoptosis 
Apoptosis can be triggered by binding of FasL to Fas. That results in exposure 
of DD and binding of FADD, which then cleaves pro-caspase-8. In cells 
undergoing Type I apoptosis, caspase-8 can cleave pro-caspase-3, which is a 
hallmark of apoptosis. In cells undergoing Type II apoptosis, caspase-8 
cleaves BID to tBID. This activates Bax and Bak resulting in the 
permeabilization of the mitochondrial membrane and the release of 
cytochrome C. Cytochrome C then forms the apoptosome with Apaf-1, which 
then cleaves caspase-3 to induce apoptosis. This figure was modified from 
Houston, A. et al.47. 
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and myeloid cell leukemia sequence 1 (MCL-1). Following permeabilization of 
the outer mitochondrial membrane, cytochrome C is released. This event is 
considered to be the point of no return for cells undergoing apoptosis. The 
release of cytochrome C leads to the formation of the apoptosome, a 7 subunit 
protein complex consisting of cleaved cytochrome C and apoptotic protease 
activating factor 1 (Apaf-1). The apoptosome then cleaves pro-caspase-9 into 
caspase-9, which cleaves and activates pro-caspase-3, which leads to cell 
death. 
1.2.6. Lymphocyte cytotoxicity 
 As CD8+ T cells differentiate into CTLs, they upregulate proteins 
responsible for killing, namely FasL, perforin, and a number of granzymes. 
These proteins are contained within LGs, which are secretory lysosomes.  LGs 
are also expressed and released by natural killer (NK) cells, which use the 
same cytotoxic machinery as CTLs. The contents of LGs are released 
following TCR stimulation of CTLs. Here we present the mechanics of how the 
release of FasL, granzymes, and perforin are coordinated to induce apoptosis. 
One way that cytotoxic lymphocytes induce death in target cells is 
through Fas. Ligation of FasL to Fas induces signaling that leads to apoptosis. 
Cell death through Fas signaling occurs more slowly than granzyme and 
perforin mediated cytotoxicity but is still an important mechanism for inducing 
cell death49. There are five granzymes in humans and ten in mice50. 
Granzymes are serine proteases that have many targets within cells. 
Granzyme B is the most highly expressed and most studied granzyme51. In 
CTLs, granzyme B is one of the most highly expressed proteins and is 
expressed at similar levels to actin. Targets of granzyme B include but are not 
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limited to caspase-3, caspase-7, caspase-9, and caspase-10. There have 
been reports that granzyme B cleaves BID into tBID; however, these reports 
have been disputed52,53. Granzymes have also been shown to play a role in 
host defense against intracellular pathogens54,55. Granzyme A induces cell 
death by triggering DNA damage51. The other granzymes induce cell death 
through a variety of other mechanisms, many of which are not known. Cells 
treated with granzymes do not undergo apoptosis as granzymes are unable to 
penetrate the plasma membrane. Cytotoxic lymphocytes puncture the plasma 
membrane using perforin, a protein that forms pores in a calcium dependent 
manner. Perforin is stored in an inactive form in LGs at low pH. Upon 
lymphocyte activation, perforin is released and forms pores 12-17nm in 
diameter on the target cell membrane56.  
 The current model for perforin and granzyme mediated death begins 
with the cytotoxic lymphocyte releasing the contents of LGs into the space 
between itself and target cell (Figure 1.5)57. Perforin forms holes in the plasma 
membrane, which trigger an influx of Ca2+ in the target cell57,58. Perforin has 
been found to form pores within minutes of cytotoxic lymphocyte-target cell 
interactions59. The influx of Ca2+ initiates membrane repair mechanisms, which 
involve endocytosis of the target cell plasma membrane for repair57. This 
brings perforin and granzyme from the extracellular space into the target cell in 
endosomes. Inside endosomes, perforin makes holes in the membrane 
releasing granzymes into the cytoplasm. Once in the cytoplasm, granzymes 
induce cell death through caspase dependent and independent mechanisms 
as discussed above60. 
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Figure 1.5 Cartoon of perforin and granzyme release and entry into target 
cells 
(1) Lytic granules are secreted from the cytotoxic lymphocyte into the space 
between the lymphocyte and target cell through the immunological synapse. 
Perforin forms holes in the target cell plasma membrane, which triggers an 
influx of Ca2+ (2). This influx of calcium initiates membrane repair mechanisms 
that result in membrane resealing (3). This then results in endocytosis of the 
plasma membrane, creating endosomes containing perforin and granzyme (4). 
Inside the endosomes, perforin makes holes in the endosome membrane 
releasing granzyme, which triggers apoptosis. This figure was modified from 
Keefe, D. et al.57. 
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Researchers have examined the roles of granzyme A, granzyme B, and 
perforin in spontaneous and subcutaneous tumor growth experiments. Perforin 
is indispensible for tumor rejection; however both granzyme A and granzyme 
B are not required61. This suggests that there is some overlapping function for 
granzymes and that if one granzyme is missing others are able to compensate 
for it. Experiments to assess cytotoxicity of cells isolated from mice knocked 
out for every granzyme have not been performed. However, mice lacking 
perforin have a dramatic defect in cytotoxicity of CTLs and NK cells61,62.  
Perforin deficient mice also experience increased rates of tumor 
development in the methylcholanthrene (MCA) induced tumor model63. These 
experiments demonstrate the unique role perforin plays in cytotoxicity. Perforin 
appears to have an additional role in regulation of the immune system as 
patients with familial hemophagocytic lymphohistiocytosis have nonsense 
mutations in the perforin gene64. The importance of perforin to suppress the 
immune system has also been shown for mice infected with LCMV clone 13. 
Perforin deficient mice infected with LCMV clone 13 experienced decreased 
survival due to over expansion of CD8+ T cells65. This stems from uncontrolled 
inflammation produced by viral specific CD8+ T cells. Treating mice with 
antibodies to deplete CD8+ T cells and to block cytokines prolongs survival66. 
Furthermore, mice deficient for both perforin and Fas show an increase in 
lymphoproliferative disease relative to mice deficient for Fas and heterozygous 
for perforin65. These results highlight a key role for perforin and Fas outside of 
lymphocyte cytotoxicity in maintaining immune homeostasis. 
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1.2.7. Mechanobiology of T cell activation 
Recent work has provided insight into how the TCR can distinguish 
single amino acid substitutions in short peptides. Previous research has 
shown that the ζ-chain of the TCR undergoes conformational changes to 
expose phosphorylation sites in its ITAM domains67. Other work has shown 
that the TCR is an anisotropic mechanosensor that requires force orthogonal 
to the IS for the induction of calcium signaling68. The model that these two 
observations suggest is that force is required to expose ITAM domains on the 
TCR, which leads to the induction of membrane proximal signaling. 
Furthermore, the TCR-pMHC interaction has been shown to function as a 
catch bond69. A catch bond is a type of bond in which application of a force 
increases the lifetime of the interaction. It was shown that the capacity to form 
a catch bond plays a critical role in enabling the TCR to discriminate between 
high and low affinity agonists69. Together these studies demonstrate the 
important role of mechanobiology in TCR activation and signaling. 
The IS has been shown to be a dynamic and physical structure that is 
capable of exerting mechanical force70,71. Naïve T cells have been shown to 
exert mechanical force on polydimethylsiloxane (PDMS) pillars coated with 
activating proteins71. It is conceivable that T cells could exert forces as a way 
of sensing the mechanical properties of activating surfaces. This is supported 
by previous research demonstrating that T cells are more strongly activated on 
softer rather than stiffer PDMS surfaces, as measured by cytokine production 
and proliferation72. Activating peripheral blood mononuclear cells (PBMCs) on 
softer surfaces with CD3/CD28 antibodies tended to increase shedding of 
CD62L, which is a consequence of T cell activation72. This is intriguing 
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because the opposite phenomenon has been observed for naïve mouse T 
cells activated on polyacrylamide surfaces with CD3/CD2873. Possible 
explanations for this discrepancy include a difference between human and 
mouse cells. It is also possible T cells respond differently to antibodies on 
PDMS and polyacrylamide surfaces. Further research is needed to understand 
the precise role of surface tension on T cell activation. Yet, these studies are 
intriguing and support the concept that signaling and cell biology are not 
merely biochemical reactions. These observations show that mechanical 
properties of biology are important factors that have been largely overlooked 
in immunology until recently. 
1.3. Immune system and cancer 
The connection between the immune system and tumor development 
has been active area of research for decades. The idea that the immune 
system is capable of surveying a host and eliminating cancer was first coined 
cancer immunosurveillance by Sir Macfarlane Burnet in 195774. This idea was 
quickly abandoned for lack of evidence. The first evidence of this phenomenon 
came from carcinogen induced cancer models75. This concept has evolved 
into the model of immunoediting75,76. This term encapsulates 
immunosurveillance as well as conveying the notion that the immune system 
alters the tumor and shapes its development. The theory of cancer 
immunoediting describes three components of the process, termed the three 
E’s of immunoediting76. In the first stage, the immune system actively 
eliminates transformed cells preventing the formation of a tumor76. In the 
second stage, the transformed cells come to an equilibrium with the immune 
system76. In the third stage, the transformed cells escape containment by the 
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immune system and grow out, forming a tumor76. Since the emergence of the 
immunoediting model, there has been a tremendous amount of research 
examining the precise relationship between the immune system and cancer. 
As part of this research, the immune system has been identified as playing a 
distinct role in the formation of tumors.  
The tumor microenvironment is a dynamic landscape with many 
different immune cell infiltrates including different types of T cells, 
macrophages, and myeloid cells. These cells can promote both an anti-tumor 
immune response and tumorigenesis77. For instance, macrophages can have 
an M1 or M2 phenotype, and they play different roles in tumor progression. M1 
macrophages produce pro-inflammatory cytokines and act as APCs, whereas 
M2 macrophages promote tumorigenesis and produce anti-inflammatory 
cytokines77. T cells also have both tumorigenic and anti-tumor effects. Both 
CD4+ T cells and CD8+ CTLs are present in tumors. One subtype of CD4+ T 
cell found in tumors is Tregs. In healthy individuals, Tregs provide 
immunosuppressive functions78. Without Tregs, mice and patients develop 
severe autoimmunity. However, in the tumor microenvironment, Tregs have a 
complex and poorly understood role. The presence of Tregs in tumors has 
been correlated with a poor prognosis in the case of breast and hepatocellular 
carcinomas79,80. Alternatively, the presence of high numbers of Tregs in 
colorectal cancer is an indicator of a good prognosis81. As CTLs infiltrate the 
tumor, they are exposed to the immunosuppressive environment created by 
macrophages, Tregs, and other cells. They are also exposed to chronic 
stimulation through their TCR and pro-inflammatory cytokines. Chronic 
overstimulation of the TCR in the tumor environment causes CTLs to become 
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dysfunctional and express various inhibitory markers such as PD-1, TIGIT, 
and others41,42. There is a concerted effort in the scientific community to 
reverse these immunosuppressive effects and to use the immune system as a 
cancer treatment. Some of these approaches will be discussed next. 
1.4. Cancer Immunotherapies  
Attempts to harness the immune system to treat illnesses predate a 
simple understanding of the immune system with vaccines. More recently, 
physicians have been using the adaptive immune system in their fight against 
cancer. In the last several years there have been a number of significant 
breakthroughs, which have generated a great deal of interest. 
1.4.1.  Checkpoint blockade 
The development of checkpoint blockade emerged from the discovery 
of CD28 and co-stimulation82. When T cells encounter an APC, they receive 
stimulation through their TCR. When a naïve T cell encounters an APC, its 
activation depends on receiving a second signal through CD28. Co-stimulatory 
ligands for CD28 include B7-1 and B7-2. Inhibitory receptors for B7-1 and B7-
2 have also been discovered, which include cytotoxic T-lymphocyte-
associated protein 4 (CTLA-4)83. Treating T cells with antibodies to block 
CTLA-4 was found to increase their proliferation; whereas treating T cells with 
antibodies to crosslink CTLA-4 reduced their proliferation83,84. In vitro, CTLA-4 
has been shown to compete with CD28 for B7 molecules on the surface of the 
APC, which results in reduced co-stimulation of T cells83. Further studies 
showed that treatment of tumor bearing mice with CTLA-4 blocking antibodies 
resulted in a significant improvement in the anti-tumor responses85. PD-1 is 
structurally and functionally similar to CTLA-4 and has been shown to be a 
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negative regulator of T cell activation86. PD-1 is thought to attenuate TCR 
signaling by inhibiting the phosphorylation of ZAP70, CD3ζ, and CD2887,88. 
This work has led to many clinical trials, which found that treatment of cancer 
patients with blocking antibodies for CTLA-4 and PD-1 resulted in a 
remarkable increase in survival. Clinical trials have been performed with a 
variety of cancers but the most success has been for patients with metastatic 
melanoma89. While the mechanism for how CTLA-4 and PD-1 blockade work 
in vitro is well understood, it is unclear how precisely they work in vivo90. 
Understanding this is critical for improving and developing new cancer 
therapies.  
Following the discovery and success of monoclonal antibodies targeting 
the receptors CTLA-4 and PD-1, there has been a great interest in developing 
similar molecules to other receptors89,91,92. Additional targets include 
Programmed death-ligand 1 (PD-L1), V-domain Ig suppressor of T cell 
activation (VISTA), Hepatitis A virus cellular receptor 2 (TIM-3), and 
Lymphocyte-activation gene 3 (LAG-3)93. There are also efforts to determine 
whether the checkpoint blockade approach can be applied to other types of 
cancer besides metastatic melanoma94. 
One challenge that has emerged with new cancer therapies is that it is 
difficult to determine which treatment is best for each patient. This 
necessitates the discovery of good biomarkers that could identify the right drug 
for a patient. This is especially true given the low response rates of some 
forms of cancer to checkpoint blockade including non-small cell lung cancer 
and renal cell carcinoma with response rates under 20% and 30% 
respectively92. Biomarkers include PD-L1 expression, mutational burden, and 
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the number of T cell infiltrates in the tumor92. However, the utility of these 
biomarkers is limited by tumor heterogeneity, inconsistent lymphocyte 
infiltration, insufficient biopsies, and other reasons. Furthermore, the fact that 
we do not understand the precise mechanism for checkpoint blockade further 
limits our ability to identify biomarkers to predict responses. 
1.4.2. Adoptive cell therapies 
Adoptive cell therapies (ACT) are another promising strategy for using 
the immune system to treat cancer. These treatments rely on isolating 
lymphocytes from the peripheral blood of patients and expanding them ex 
vivo95–98. While they are being expanded, lymphocytes are sometimes treated 
to express proteins to modulate their function such as chimeric antigen 
receptors (CARs). The CAR is a fusion protein consisting of an extracellular 
domain of a single chain antibody targeting a specific antigen, a 
transmembrane domain, and various intracellular signaling domains99. There 
is some variety with respect to which signaling domains are used and 
optimizing the motifs is an area of active research. The CARs that have had 
the most success are the ones targeting B cell malignancies via the CD19 
antigen, which is very specifically expressed on B cells99. On-target off-tumor 
side effects are a concern when the CAR antigen is widely expressed on non-
cancerous cells, even at low levels. At least one patient has died from cytokine 
release syndrome likely due to on-target but off-tumor side effects following 
treatment with a CAR against human epidermal growth factor receptor 2 
(HER-2)100. Furthermore, as blood cancers are liquid tumors, they do not have 
the same immunosuppressive environment of solid tumors, which was 
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previously discussed. These factors hint that it might be difficult to design CAR 
treatments that would be effective in solid tumors. 
Other types of ACT involve expanding patients’ lymphocytes and 
transferring them back into the patient without transfecting them to express 
novel receptors. Steven Rosenberg at the National Institutes of Health has 
pioneered some of this work. He has performed clinical trials where polyclonal 
tumor infiltrating lymphocytes were taken from patients, expanded, and 
transferred back into the patients. Upon transfer, patients can experience a 
dramatic reduction in tumor mass98. This approach has many benefits over 
CAR therapies including success in solid tumors. However, one of the 
limitations of this approach is that there is a large amount of patient-to-patient 
variability. This makes a standard protocol difficult to develop as every patient 
has a unique repertoire of T cells and a unique cancer. 
One of the primary drawbacks to ACTs is the significant toxicity 
observed in the clinical trails101. This has led to several trials being halted. One 
of the ways to reduce the toxicity of ACT, in principle, is by using molecular 
switches to turn on or off the transferred cells. For instance, synthetic Notch 
receptors have been used to turn on expression of a CAR only when a cell has 
encountered a second signal102. While cancer treatments involving these 
molecular switches will be more complicated for physicians to administer, they 
also provide increased flexibility and likely improved safety, which are both 
lacking for traditional CARs. There are also switches that turn on suicide 
genes to halt the progression of cytokine release syndrome101. 
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1.5. Conclusion 
The development of successful ACTs relies on a detailed 
understanding of T cell activation, migration, and cytotoxicity. Here we 
examine the mechanism behind the increase in CTL cytotoxicity observed 
upon PTEN depletion. PTEN depletion increases CTL force exertion in 
response to antigen in the plane of the IS and orthogonal to the IS. We 
connect this increase in force exertion with faster perforin pore formation. We 
demonstrate that tenser plasma membranes results in increased susceptibility 
of cancer cells to perforin and CTL lysis. We further implicate force in 
cytotoxicity by establishing a spatiotemporal relationship between force 
exertion and degranulation events. 
Given the increased cytotoxicity of PTEN depleted cells in vitro, we next 
examined whether PTEN depletion could be used as a way to enhance tumor 
rejection in a transplantable melanoma model of ACT. PTEN depleted cells 
were found to have reduced anti-tumor effects in vivo. Tumor rejection 
requires both CTL persistence and cytotoxicity. PTEN depleted cells were 
found to have a defect in persistence, which we investigated to understand 
how migration, survival, and proliferation contribute to persistence. T cells 
depleted for PTEN were found to have defective migration, reduced 
homeostatic proliferation, and increased survival. This work highlights the 
importance of homeostatic expansion and migration as critical components of 
ACT and illuminates them as functional targets for improving ACTs in the 
future. 
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CHAPTER 2: CYTOTOXIC T CELLS USE 
MECHANICAL FORCE TO POTENTIATE 
TARGET CELL KILLING* 
2.1. Introduction 
Cells exchange information through adhesive and highly dynamic cell-
cell interactions. Within these contacts, communicative chemical 
processes are exposed to micrometer scale membrane 
and cytoskeletal movements capable of imparting substantial mechanical 
force. It is known that cells use applied force to sense the physical properties 
of their environment and translate this information into afferent chemical 
signals that flow into the cell. This process, called mechanotransduction, plays 
critical roles in the activation and differentiation of multiple cell types103,104. In 
principle, force could also modulate intercellular communication, particularly in 
close cell-cell interactions where movement on one side of the interface 
induces physical changes on the other side. Whether cell-derived forces 
actually contribute to the transmission of efferent signals in this manner, 
however, remains unclear. 
Cell-cell contacts in the immune system represent an interesting 
experimental context for exploring this question because they are structurally 
dynamic and also mediate a substantial amount of information transfer. One of 
                                            
* †Basu, R., †Whitlock, B.M., †Husson, J., Le Floc’h, A., Jin, W., Oyler-Yaniv, A., 
Dotiwala, F., Giannone, G., Hivroz, C., Lieberman, J., Kam, L.C., Huse, M. (2016). Cytotoxic T 
Cells Use Mechanical Force to Potentiate Target Cell Killing. Cell, 165(1), 100–110. 
http://doi.org/10.1016/j.cell.2016.01.021 
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the most important of these interactions is the IS used by CTLs to instruct 
infected or transformed target cells to die. Target cell killing is crucial 
for adaptive immune responses against intracellular pathogens, and it also 
plays a central role in several cell-based anti-cancer immunotherapies97. IS 
assembly is triggered by the recognition of pMHC on a potential target 
by TCRs on the CTL. Once the IS forms, CTLs secrete a toxic mixture of 
proteins into the synaptic space that includes perforin and 
several granzyme proteases105. Perforin is a hydrophobic molecule that forms 
calcium (Ca2+)-dependent pores in the target cell membrane. This induces a 
repair response that enables granzymes to access the target cell cytoplasm, 
where they induce apoptosis57,58. 
Perforin and granzymes are stored in 
secretory lysosomes called lytic granules, which cluster around 
the centrosome in activated CTLs. During IS formation, the centrosome 
reorients to the center of the contact, placing the granules in close apposition 
to the synaptic membrane14. This polarization event is thought to enhance the 
potency and the specificity of killing by promoting directional release of granule 
contents toward the target. Recent results, however, indicate that CTLs kill 
quite effectively in the absence of centrosome reorientation, suggesting there 
are additional mechanisms by which the IS potentiates cytotoxicity106. 
IS formation also involves intense remodeling of filamentous actin (F-
actin), which controls both the growth and the organization of the interface107. 
Recently, we demonstrated that PI3K activity stimulates actin polymerization 
within the IS by recruiting Dock2, an exchange factor for the Rho 
GTPase Rac8. CTLs lacking Dock2 form miniaturized synapses that are 
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structurally unstable. Conversely, depletion of PTEN, a lipid phosphatase that 
antagonizes PI3K, markedly enhances IS growth. Interestingly, whereas 
Dock2-deficient CTLs kill target cells poorly, PTEN-deficient CTLs exhibit 
dramatically enhanced cytotoxicity8. These results establish an intriguing link 
between target cell killing and F-actin remodeling at the IS. The mechanistic 
basis for this relationship, however, has remained unclear. 
Synaptic F-actin is highly dynamic, exhibiting constant retrograde flow 
toward the center of the IS as well as bursts of anterograde flow in the 
opposite direction70,108,109. These and other effects enable the T cell to impart 
nanonewton scale forces against the target cell71,110. In the present study, we 
combined specific perturbations of PI3K-Dock2 signaling with single cell 
biophysical approaches to investigate the impact of synaptic forces on CTL 
function. We found that force exertion at the IS potentiates killing by straining 
the target cell surface and thereby enhancing the pore forming activity of 
perforin. These results demonstrate that T cells mix physical and chemical 
outputs to enhance their effector responses and reveal an unexpected role 
for cellular mechanics in intercellular communication. 
2.2. Results 
2.2.1. Cytotoxicity Correlates with Synaptic Force Exertion  
The killing phenotypes observed in PTEN- and Dock2-deficient CTLs 
implied an important role for PI3K-dependent F-actin remodeling in cellular 
cytotoxicity. To investigate this relationship, we first examined the distribution 
of lytic granules in CTL-target cell conjugates. CTLs expressing the OT-1 
TCR, which recognizes the ovalbumin257–264 peptide (OVA) bound to the class 
I MHC molecule H2-Kb, were transduced with short hairpin RNA (shRNA) 
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against PTEN (shPTEN) or Dock2 (shDock2) or with nontargeting control 
shRNA (shNT) (Figure 2.1). They were then mixed with OVA-loaded EL4 
target cells and the resulting conjugates fixed and stained to visualize lytic 
granules (Figure 2.2A). Suppression of Dock2 or PTEN had no effect on 
granule polarization to the IS (Figure 2.2B), indicating that intracellular 
trafficking of cytotoxic cargo does not involve PI3K-Dock2 signaling. We also 
quantified granule release (called degranulation) from CTLs by measuring 
surface exposure of the granule resident protein Lamp1 after stimulation with 
target cells. This response was unaffected by depletion of PTEN or Dock2 
(Figure 2.2C), consistent with previous results8. Finally, we examined TCR-
induced calcium (Ca2+) flux, a requisite step for granule clustering and 
exocytosis, by imaging CTLs on glass surfaces coated with H2-Kb-OVA and 
ICAM-1 (a ligand for the αLβ2 integrin LFA-1)111,112. Dock2- and PTEN-deficient 
CTLs displayed robust Ca2+ responses that were comparable to those of shNT 
expressing controls (Figures 2.2D and 2E). Taken together, these data 
  
Figure 2.1 shRNA-Mediated Suppression of Dock2 and PTEN 
Representative western blots showing typical levels of Dock2 and PTEN 
depletion in OT1 CTLs expressing shDock2 and shPTEN, respectively, 
relative to controls expressing shNT. Actin served as a loading control. Data 
are representative of at least 5 independent experiments. Audrey Le Floc'H 
performed these experiments. 
   
30 
 
  
Figure 2.2 PTEN and Dock2 Are Not Required for Lytic Granule 
Polarization and Ca2+ Flux 
(A and B) OT1 CTLs expressing the indicated shRNAs were mixed with OVA-
loaded EL4 cells, fixed, and stained for pericentrin and Lamp1 to visualize the 
centrosome and lytic granules, respectively. (A) Left: brightfield image of a 
representative CTL-target cell conjugate. Right: corresponding fluorescence 
image, with white lines indicating CTL boundaries. (B) Left: polarization index 
was calculated using the center of gravity (COG) of the lytic granules. Right: 
quantification of lytic granule polarization index (n ≥ 37 per sample). 
Differences were not significant (two-tailed Student’s t test). (C) OT1 CTLs 
expressing the indicated shRNAs were mixed with OVA-loaded EL4 cells and 
degranulation assessed by surface exposure of Lamp1. (D) CTLs expressing 
the indicated shRNAs were loaded with Fura2-AM and imaged on glass 
surfaces coated with H2-Kb-OVA and ICAM1. Left: representative time-lapse 
montages of CTLs contacting the stimulatory surfaces. Images are 
pseudocolored with warmer colors (e.g., orange, red) indicating higher 
concentrations of intracellular Ca2+. Time in MM:SS is indicated above the 
montages. Right: mean normalized Fura ratio graphed against time. n ≥ 21 
cells per sample. All scale bars, 10 µm. Error bars denote SEM. Data are 
representative of at least two independent experiments. Audrey Le Floc'H and 
Morgan Huse performed these experiments. 
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  Figure 2.2 (continued) 
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indicate that suppression of PTEN and Dock2 does not affect granule 
polarization and fusion at the IS, implying that these perturbations influence 
cytotoxicity via a different mechanism. 
Force exertion across the IS could, in principle, provide a physical 
avenue for control of target cell killing. To investigate this possibility, we first 
asked whether PI3K-Dock2 signaling, which controls cytotoxic efficiency, 
might also regulate IS mechanics. Accordingly, we compared synaptic force 
exertion in OT-1 CTLs transduced with shNT, shPTEN, and shDock2. To 
measure forces perpendicular to the IS, we used micropipettes to place 
individual CTLs in contact with polystyrene beads coated with H2-Kb-OVA and 
ICAM-1 (Figure 2.3A). Subsequent bead displacements toward or away from 
the CTL were translated into force measurements using the known stiffness of 
the micropipette holding the bead. Contact with stimulatory beads induced a 
rapid CTL spreading response not unlike IS formation with a target cell. 
Spreading was frequently accompanied by transient pushing of the bead away 
from its initial position. This was followed in almost all cases by a pronounced 
pulling phase in which the bead became engulfed by the CTL (Figure 2.3B). 
Analysis of kymographs derived from each experimental trial enabled us to 
determine the rate of bead movement during the pulling phase of the response 
(Figure 2.3C), which is proportional to the pulling force. This parameter, called 
the loading rate, was significantly enhanced in CTLs lacking PTEN and 
markedly reduced in CTLs lacking Dock2 (Figure 2.3D). These results indicate 
that PI3K-Dock2 signaling drives force exertion perpendicular to the CTL-
target cell interface. 
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Figure 2.3 PI3K Signaling Controls Force Exertion Perpendicular to the 
IS 
 
(A) Schematic diagram of the micropipette-based system. (B) Time-lapse 
montage of a representative micropipette experiment. Dashed white line 
denotes the initial position of the bead. Time is indicated in M:SS in the bottom 
left corner of each image. (C) Kymograph of the experiment shown in (B). The 
loading rate can be derived from the slope of the red line. (D) Average loading 
rate during the pulling phase of the response, calculated for cells expressing 
the indicated shRNAs. Error bars denote SEM. n ≥ 10 cells per condition. ∗p < 
0.05, ∗∗p < 0.01, calculated by two-tailed Mann-Whitney test. All scale bars, 
5 µm. Data are representative of at least two independent experiments. 
Audrey Le Floc'H and Julien Husson performed these experiments. 
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To measure forces in the plane of the IS, we imaged OT-1 CTLs on 
arrays of polydimethylsiloxane (PDMS) micropillars bearing immobilized H2-
Kb-OVA and ICAM-1 (Figure 2.4A)71. Because the dimensions (6 µm tall, 
0.7 µm diameter) and composition of these pillars were known, observed pillar 
deflections could be converted into force vectors. OT-1 CTLs exhibited cell 
spreading and OVA-induced Ca2+ flux upon contact with the arrays, consistent 
with canonical TCR activation and signaling (Figures 2.4B and 5A). In most 
cells, spreading was associated with centrifugal pillar deflections, indicative of 
outwardly oriented forces (Figures 2.4B and 4C). After the size of the interface 
stabilized, these deflections tended to reverse polarity and point inward. The 
progression from centrifugal “spreading” to centripetal “squeezing” was 
reminiscent of the responses displayed by naive CD4+ T cells on pillar 
arrays71. However, OT-1 CTLs exerted substantially more force per pillar than 
naive cells (Figure 2.4D), and their force profiles were less symmetric71. 
Indeed, instantaneous force exertion tended to be concentrated in “hotspots” 
characterized by the strong deflection of one to three pillars (Figure 2.4B, 
green asterisks). Importantly, suppression of PTEN markedly enhanced force 
exertion on both individual pillars and also the entire array (Figures 2.4E 
and 5B). Dock2 suppression gave less conclusive results, with some 
experiments revealing a slight inhibitory effect and others indicating no 
significant difference (Figures 2.4F and 5B). It is possible that forces in the 
plane of the IS are less sensitive to reduced PI3K signaling than those in the 
orthogonal dimension. Nevertheless, when taken together with our 
micropipette data, these studies indicate that CTLs exert multidimensional 
PI3K-dependent forces against the target cell. 
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Figure 2.4 PI3K Signaling and NMII Control Force Exertion Parallel to the 
IS 
(A) Schematic diagram of the micropillar system. (B–F) CTLs expressing 
shNT, shDock2, or shPTEN were imaged on stimulatory micropillar arrays. (B) 
Time-lapse montage of a representative CTL-micropillar interaction. Time is 
indicated in the top right corner of each image. Large pillar deflections are 
indicated by yellow arrows. Green asterisks denote “hotspots” of strong force 
exertion. (C) Average projection of pillar deflections along the line connecting 
each pillar to the cell's center of gravity (COG projection) was determined for 
the CTL shown in (B) and plotted against time. (D) Aggregate plot of 
instantaneous force per pillar exerted by the CTL in (B), graphed against time. 
Pink dots denote pillars in contact with the cell, and blue dots denote pillars 
outside of the interface. Average force per pillar within the interface is shown 
in green and background force per pillar in cyan. (E and F) Total force exertion 
against the pillar array graphed versus time for CTLs expressing the indicated 
shRNAs. n ≥ 6 cells per sample. (G) CTLs treated with 50 µM blebbistatin 
(Bleb) or vehicle control (Veh) were imaged on stimulatory micropillar arrays. 
Total force exertion against the array is graphed as in (E). (H) CTLs 
expressing the indicated shRNAs were mixed 1:1 with OVA-loaded RMA-s 
cells. Specific lysis is graphed as a function of OVA concentration. All error 
bars denote SEM. Data are representative of at least two independent 
experiments. Benjamin Whitlock, Weiyang Jin, and Morgan Huse performed 
these experiments. 
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Figure 2.4 (continued) 
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Figure 2.5 Antigen-Induced Forces on PDMS Micropillar Arrays 
(A) OT1 CTLs were loaded with Fura2-AM and then imaged on micropillars 
coated with the indicated ligands (pMHC = H2-Kb-OVA). Representative time-
lapse montages are shown of CTLs coming into contact with the surface. 
Images are pseudocolored with warmer colors (e.g., orange, red) indicating 
higher concentrations of intracellular Ca2+. Scale bars, 10 µm. (B) CTLs 
expressing shNT, shDock2, and shPTEN were imaged on micropillar arrays 
coated with H2-Kb-OVA and ICAM1. Graphs show average force exertion per 
pillar versus time. n ≥ 6 cells per sample. (C) CTLs treated with 50 µM 
blebbistatin (Bleb) or vehicle control (Veh) were imaged on stimulatory 
micropillar arrays. The average COG projection (see Figure 3C) for cells in 
each condition is plotted against time. Positive values indicate centrifugal 
“spreading,” while negative values indicate centripetal “squeezing.” (D) 
Representative western blot showing typical levels of MyH9 relative to controls 
expressing shNT. Actin served as a loading control. (E) OT1 CTLs expressing 
the indicated shRNAs were mixed with OVA-loaded RMA-s target cells and 
degranulation assessed at various times by surface exposure of Lamp1. 
Although shMyH9-expressing CTLs displayed increased degranulation in this 
experiment, the result was not consistent. All error bars denote SEM. Data are 
representative of at least two independent experiments. Benjamin Whitlock, 
Weiyang Jin, and Morgan Huse performed these experiments. 
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Figure 2.5 (continued) 
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Myosin-based contractility is crucial for the generation of actin-
dependent forces in multiple cell types, and clusters of the nonmuscle myosin 
II (NMII) isoform have been observed within the T cell IS113–115. Although the 
precise function of synaptic NMII remains controversial, it is appropriately 
positioned to contribute to force exertion116. To investigate this possibility, we 
examined micropillar deflection in the presence of blebbistatin, a small 
molecule myosin II inhibitor. Blebbistatin treatment dramatically reduced force 
exertion during both the “spreading” and “squeezing” phases of the response 
(Figures 2.4G and 2.5C), indicative of an important role for NMII in IS 
mechanics. Next, we asked whether synaptic force exertion by NMII 
modulates cytotoxicity. For these experiments, we utilized shRNA knockdown 
of the myosin heavy chain MyH9 (shMyH9) to target the NMII complex 
selectively in CTLs. This strategy yielded only partial suppression of MyH9 
(Figure 2.5D), as previously reported117. CTLs expressing shMyH9 exhibited a 
subtle, but consistent killing defect that paralleled the partial knockdown of the 
protein (Figure 2.4H). Importantly, TCR-induced degranulation was not 
inhibited in these cells (Figure 2.5E), indicating that TCR activation and 
signaling remained intact. We conclude that myosin activity, like PI3K 
signaling, controls both cytotoxicity and synaptic force exertion. 
2.2.2.  PI3K signaling Accelerates Perforin Pore Formation 
Next, we re-examined how PI3K signaling affects cytotoxicity, focusing 
on events that occur downstream of perforin and granzyme secretion. Perforin 
initiates killing by forming plasma membrane pores on the target cell60. This 
event can be visualized by imaging CTLs and target cells in the presence of 
high concentration (100 µM) propidium iodide (PI)57,59. Plasma membrane 
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perforation allows PI to access the cytoplasm, rendering the target 
cell fluorescent (Figure 2.6A). To quantify the rate of perforin pore formation 
using this approach, we imaged OVA-loaded RMA-s target cells together with 
OT-1 CTLs in 50 × 50 µm PDMS microwells, which facilitate extended 
observation of individual CTL-target cell interactions (Figure 2.6B). These 
experiments revealed that CTLs expressing shPTEN were significantly more 
effective at inducing perforin pore formation than shNT expressing controls. 
The fraction of interactions associated with target cell PI incorporation was 
higher (93% for shPTEN CTLs versus 71% for shNT CTLs), and among these, 
the time delay between IS formation and PI fluorescence (influx time) was 
significantly reduced (Figure 2.6C). 
CTLs lacking PTEN exhibited higher total levels of perforin protein 
(Figure 6D), which could, in principle, explain the enhanced pore formation we 
observed. This increase in perforin expression could be reversed, however, by 
removing one copy of the prf1 gene in the context of PTEN deficiency. 
Importantly, killing by PTEN-deficient prf1+/− CTLs was essentially equivalent 
to that of PTEN-deficient prf1+/+ CTLs and substantially greater than that 
of prf1+/+ shNT controls (Figure 2.6E). Hence, it is unlikely that the accelerated 
pore formation seen in the absence of PTEN resulted from changes in perforin 
expression. Rather, PTEN suppression appeared to boost cytotoxicity by 
increasing perforin activity on a per molecule basis. 
2.2.3.  Cell Tension Potentiates Target Cell Lysis 
Biophysical studies have shown that increasing the tension of target 
membranes boosts the activity of pore forming peptides, implying that 
tangential force can reduce the energetic cost of inserting a hydrophobic  
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Figure 2.6 PTEN Deficiency Enhances Perforin Pore Formation 
(A) Schematic diagram showing perforin pore detection by PI. (B and C) CTLs 
expressing shNT or shPTEN together with cyan fluorescent protein (CFP) 
were mixed with carboxyfluorescein succinimidyl ester (CFSE)-labeled, OVA-
loaded RMA-s cells and imaged in PDMS microwells in the presence of 
100 µM PI. (B) Time-lapse montage of a representative microwell showing 
conjugate formation (magenta asterisk) and PI influx (purple arrowhead). Time 
is indicated in H:MM in the bottom left corner of each image. (C) Time 
between conjugate formation and PI influx (PI influx time) quantified for shNT 
and shPTEN expressing CTLs. Error bars denote SEM. n ≥ 65 conjugates per 
sample. P value calculated by two-tailed Mann-Whitney test.(D) Perforin (Prf) 
expression in the indicated CTLs was analyzed by western blot. Actin served 
as a loading control. (E) prf1+/+ and prf1+/− CTLs expressing the indicated 
shRNAs were mixed 1:1 with OVA-loaded RMA-s cells. Specific lysis is 
graphed as a function of OVA concentration. Data are representative of at 
least two independent experiments. Benjamin Whitlock and  Morgan Huse 
performed these experiments. 
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molecule into the bilayer118–120. Accordingly, we reasoned that synaptic forces 
might potentiate perforin pore formation by applying tension to the target cell. 
To explore the relationship between cell tension and perforin function, we grew 
adherent cells on polyacrylamide hydrogels of varying elasticity121. Cell tension 
in this culture system mirrors the underlying hydrogel; stiff hydrogels enforce 
high tension, while soft hydrogels induce the opposite effect122–125. Consistent 
with this principle, we found that B16 melanoma cells adopted a stellate 
architecture on stiff (E = 50 kPa) hydrogels characteristic of high tension, while 
on soft (E = 12 kPa) hydrogels they displayed a more collapsed morphology 
(Figure 2.7). To assess perforin pore formation under each condition, we 
treated the cells with purified perforin protein (∼1 µg/ml) in the presence of 
100 µM PI (Figure 2.8A). Although the capacity of perforin to induce PI influx 
varied from day to day, we consistently observed that cells on 50 kPa 
substrates were more sensitive to pore formation than those on 12 kPa 
substrates, implying that increased cell tension potentiates perforin activity 
(Figures 2.8B, 8C, and 2.9A). 
Next, we investigated whether target cell tension similarly modulates 
CTL-mediated killing. OT-1 CTLs were added to OVA-loaded B16 cells grown 
on stiff or soft substrates and target cell lysis measured by the release of 
lactate dehydrogenase (LDH), a cytoplasmic enzyme (Figure 2.8D). Killing 
was significantly enhanced on 50 kPa hydrogels relative to 12 kPa hydrogels, 
despite equivalent levels of TCR-induced degranulation (Figures 2.8E 
and 2.10). Importantly, target cell killing by the small molecule staurosporine, 
which induces apoptosis in multiple cell types, was unaffected by substrate 
elasticity (Figures 8F and 8G). B16 cells grown on stiff matrices are therefore 
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not intrinsically less viable. Rather, they are selectively sensitized to perforin-
dependent killing. 
Cell tension is imposed both by the cytoskeletal cortex and by the 
plasma membrane. To determine the relative contributions of membrane and 
cortical tension to perforin function, we assessed pore formation in the 
presence of reagents that alter the two parameters differentially 
(Figure 2.11A). Blebbistatin, by inhibiting myosin II, reduces cortical tension 
while increasing membrane tension126,127. By contrast, the 
actin depolymerization agent latrunculin A reduces both parameters128,129. 
Treatment of adherent B16 cells with latrunculin A substantially decreased 
pore formation by purified perforin, while blebbistatin reproducibly enhanced it  
Figure 2.7 Hydrogel Stiffness Controls Cell Morphology 
B16 cells were cultured overnight on fibronectin-coated hydrogels of varying 
elasticity. Representative brightfield images show that cells spread on stiff (E = 
50 kPa) substrates and adopt a more collapsed morphology on soft (E = 12 
kPa) matrices. Data are representative of five independent experiments. 
Roshni Basu performed these experiments. 
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Figure 2.8 Cell Tension Promotes Perforin Pore Formation and CTL-
Mediated Killing 
(A–C) B16 cells were cultured overnight on stiff (E = 50 kPa) or soft (E = 
12 kPa) hydrogels, stained with Hoechst 33342, and treated with the 
indicated dilutions of perforin (1:1,000 ≈1 µg/ml final concentration) in the 
presence of 100 µM PI. (A) Schematic diagram of the perforation assay. 
(B) Representative images before and after perforin treatment on both stiff 
(top) and soft (bottom) hydrogels. Perforated cells were identified by their 
PI+ nuclei. (C) Quantification of a representative perforation experiment on 
hydrogels. Total cell counts are shown in parentheses above each bar. (D) 
Schematic diagram of a B16 killing assay on hydrogel substrate. (E) OT1 
CTLs were added to OVA-loaded B16 cells grown on stiff or soft hydrogels. 
Specific lysis was quantified by LDH release at the indicated effector to target 
(E:T) ratios. (F) Schematic diagram of staurosporine-induced apoptosis on 
hydrogel substrate. (G) B16 cells grown on stiff or soft hydrogels 
were exposed to the indicated concentrations of staurosporine. Apoptosis was 
quantified by LDH release. Error bars denote SEM. Data are representative of 
at least two independent experiments. Roshni Basu, Benjamin Whitlock, and 
Morgan Huse performed these experiments. 
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Figure 2.8 (continued) 
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Figure 2.9 Cell Tension Modulates Perforin Pore Formation 
Replicate experiments for Figures 2.8C, 11B, and 11D. (A) Quantification of 
perforin pore formation in B16 cells grown on stiff (E = 50 kPa) or soft (E = 12 
kPa) fibronectin-coated hydrogels. (B) Quantification of perforin pore formation 
in the presence of 7.5 µM latrunculin A (Lat A) or vehicle control (Veh). (C) 
Quantification of perforin pore formation in the presence of the indicated 
concentrations of blebbistatin (Bleb) or Veh. (D) Quantification of perforin pore 
formation in hypertonic (Hyper), hypotonic (Hypo), and isotonic (Iso) medium. 
A 1:1000 dilution of perforin was used in all experiments except the left graph 
in (A), which was performed using a 1:25 dilution of a low concentration prep. 
In all graphs, total cell counts are shown in parentheses above each bar. 
Roshni Basu, Benjamin Whitlock, and Morgan Huse performed these 
experiments. 
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Figure 2.10 Matrix Stiffness Does Not Alter TCR-Induced Degranulation 
B16 cells were cultured overnight on fibronectin-coated hydrogels, loaded with 
OVA as necessary, and then mixed with OT1 CTLs. Representative histogram 
plots show T cell degranulation on stiff (50 kPa, above) or soft (12 kPa, below) 
matrices, as assessed by Lamp1 staining. Unstimulated samples (Unstim, no 
OVA) are shown in solid gray, and stimulated samples (Stim, OVA) in black 
outline. Mean Fluorescence Intensity (MFI) is indicated for each curve. Data 
are representative of two independent experiments. Roshni Basu performed 
these experiments. 
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(Figures 2.11B, 2.9B, and 9C). These results suggested that membrane 
tension, rather than cortical tension, controls perforin activity. To further test 
this idea, we treated cells with hypotonic and hypertonic buffers, which 
increase and decrease, respectively, membrane tension (Figure 2.11C)126. 
Pore formation was enhanced by hypotonic buffer and suppressed by 
hypertonicity (Figures 2.11D and 2.9D), further supporting the idea that 
perforin and membrane tension function synergistically. 
2.2.4.  Synaptic Force Exertion is Coordinated with 
Degranulation 
Finally, we examined whether perforin release is spatiotemporally 
correlated with the application of force at the IS, using a degranulation 
probe containing a pH-sensitive GFP (pHluorin) attached to the C-terminal 
domain of Lamp1130. pHluorin-Lamp1 is sorted into lytic granules, where its 
fluorescence is quenched by the acidic environment. Granule fusion with the 
plasma membrane, however, neutralizes the pH around the pHluorin, allowing 
it to fluoresce. When CTLs expressing pHluorin-Lamp1 were imaged on 
PDMS micropillars coated with H2-Kb-OVA and ICAM-1, degranulation events 
appeared as abrupt increases in green fluorescence within the interface 
between the CTL and the array (Figures 2.12A and 12B). Most events 
occurred within 5 min of initial contact (Figure 2.12C) and many seemed to be 
closely associated with hotspots of strong force exertion (Figure 2.12D). 
To quantify the relationship between degranulation and force, we 
computed the distance between each granule fusion event and the closest 
pillar experiencing strong deflections during that time (called the distance to 
displaced pillar [DDP]. We then compared each value to a null distribution  
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Figure 2.11 Membrane Tension Potentiates Perforin Pore Formation 
(A) Diagram schematizing the effects of blebbistatin (Bleb) and latrunculin A 
(Lat A) on cortical (C) and membrane (M) tension. Lamellipodial F-actin and 
stress fibers are indicated in orange. (B) B16 cells cultured on plastic were 
treated with perforin (1:1,000 dilution) in the presence of 100 µM PI and either 
100 µM Bleb, 7.5 µM Lat A, or vehicle control (Veh) as indicated. Perforation 
was quantified by PI incorporation. (C) Diagram schematizing the effects of 
hypotonic (Hypo) or hypertonic (Hyper) medium on membrane tension. (D) 
B16 cells cultured on plastic were treated with perforin (1:1,000 dilution) in the 
presence of 100 µM PI either in isotonic (Iso), hypotonic, or hypertonic 
medium as indicated. Perforation was quantified by PI incorporation. In (B) 
and (D), total cell counts are shown in parentheses above each bar. Data are 
representative of three independent experiments. Roshni Basu performed 
these experiments. 
   
60 
 
  
   
61 
 
  
Figure 2.11 (continued) 
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Figure 2.12 Degranulation Is Spatiotemporally Correlated with Force 
Exertion at the IS 
(A) Diagram schematizing fluorescent detection of degranulation during a 
micropillar experiment. (B–I) CTLs expressing pHluorin-Lamp1 were imaged 
on stimulatory micropillar arrays. (B) Representative time-lapse montage 
showing pillar deflections during a degranulation event (indicated by the yellow 
arrowhead). Time is indicated in M:SS in the top right corner of each image. 
(C) Graph of the offset time between contact formation and degranulation 
(degranulation time). (D) Graphical representation of the pillar array in (B), with 
the degranulation position depicted as a green circle and the cell envelope at 
the moment of degranulation shown in black. Pillars are color-coded based on 
their average deflection during the degranulation. Warmer colors (e.g., orange, 
red) denote stronger deflections. The DDP for this degranulation is indicated 
by the double-headed white arrow. (E) Histogram plot derived from the 
experiment in (B) showing the DDP for each position in the CTL interface. The 
mean value for the distribution is denoted by the vertical cyan line. The vertical 
green line indicates the DDP for the degranulation itself. (F) DDPs of 
degranulation (Degran) were compared to the mean values of their paired null 
distributions. ∗∗∗p < 0.001, calculated by two-tailed paired t test. (G) Schematic 
diagram of the CTL-array interface showing the radial shells used for spatial 
analysis. (H and I) The radial distribution of total force exertion (H) and 
degranulation position (I) in degranulating cells. Color-coding of the bars 
corresponds to the shells shown in (G). Gray bars indicate the spatial 
distribution that would be expected by chance (outer shells are larger than 
inner ones). All error bars denote SEM. For (C), (F), and (I), n = 49 
degranulation events pooled from three independent experiments. Benjamin 
Whitlock, Weiyang Jin, and Morgan Huse performed these experiments. 
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  Figure 12 (continued) 
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generated by performing the DDP calculation for every x-y position within the 
interface between the CTL and the array (Figure 2.12E). DDP values 
associated with degranulation events were significantly lower than the mean 
values of their paired null distributions, indicating that the observed coupling 
between granule release and pillar deflection did not occur by chance 
(Figure 2.12F). We also quantified the radial distribution of degranulation and 
force exertion within the IS (Figure 2.12G) and found that both parameters 
were enriched within an annular region slightly more than halfway between the 
center of the IS and its outer edge (Figures 2.12H and 12I). Taken together, 
these results suggest that CTLs spatiotemporally coordinate cytolytic secretion 
with the local application of force, and they also identify a domain within the IS 
in which these interactions occur. 
Could forces within this degranulation zone apply enough membrane 
tension to potentiate perforin pore formation? To address this question, we 
first determined the membrane tension change necessary to sensitize a cell to 
perforin. Using an established approach in which an optical trap is used to pull 
a thin tether of membrane from the cell surface (Figures 2.13A and 13B), we 
calculated the membrane tension of adherent B16 cells to be 100 µN/m131. In 
the presence of latrunculin A, which protects cells from perforin pore formation 
(Figures 2.11B and 2.9B), membrane tension decreased to 15 µN/m. These 
data suggest that an ∼85 µN/m difference in membrane tension (equivalent to 
85 × 10−18 J/µm2) is sufficient to make perforin pore formation more 
energetically favorable (Figure 2.13C). Assuming a pore size of 15 nm, this 
tensional difference implies a free energy change of 1.5 × 10−20 J per pore. In 
micropillar experiments, we routinely observed pillar deflections of >1 µm  
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Figure 2.13 Membrane Tension of B16 Target Cells 
(A) DIC image showing a membrane tether connecting a B16 cell to a 2 µm 
diameter polystyrene bead, which is held in an optical trap. (B) Membrane 
tethers were generated from B16 cells treated with 5 µM Latrunculin A (Lat A) 
or vehicle control (Veh) as indicated. Tether forces were determined from the 
displacement of the bead within the optical trap (n ≥ 15 for each sample). (C) 
Schematic diagram of the reaction coordinate for perforin pore formation in a 
membrane, illustrating how increased membrane tension can effectively 
reduce the activation barrier of the process. ΔGP = free energy of pore 
formation, ΔGT = free energy of tension release. Roshni Basu performed 
these experiments. 
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within force exertion hotspots. Each of these strong deflections required >340 
pN of force (Figure 2.4D), implying the transfer of >170 × 10−18 J of 
mechanical energy within an ∼1 µm2 region of the array. This degree of energy 
transmission (170 × 10−18 J/µm2) compares favorably with the tensional 
change (85 × 10−18 J/µm2) demonstrated by the tether experiments to 
modulate perforin activity, and it would be sufficient, in principle, to 
mechanically potentiate a large number of pores. Hence, under conditions of 
close synaptic contact, CTLs should be capable of locally sensitizing the target 
cell membrane to perforin. 
2.3. Discussion 
Communication between immune cells is generally presented as a 
chemical process based on ligand recognition by receptors. It is becoming 
increasingly clear, however, that mechanical forces at cell-cell interfaces are 
necessary both to enable and to regulate communicative chemical 
interactions. Recent studies have documented the importance of cytoskeletally 
driven pulling for receptor activation and antigen uptake, which are both 
processes that mediate information flow into the lymphocyte69,132,133. Our 
results demonstrate that physical forces can also modulate information flow 
out of the cell, in this case by potentiating the activity of a secreted protein, 
perforin. This synergy between applied force and outgoing chemical signals, 
which we term mechanopotentiation, conceptually expands the purview of 
cellular mechanics as an active mediator of not only afferent but also efferent 
intercellular communication. 
It has been proposed that the IS enhances the intensity and specificity 
of intercellular communication by restricting the diffusion of secreted 
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factors13,134,135. Studies of cytokine-mediated communication, however, 
indicate that soluble proteins escape the T cell-target cell interface very 
quickly136–138. An alternative strategy for boosting selectivity and efficiency 
would involve locally increasing the specific activity of secreted molecules. 
Synaptic mechanopotentiation of perforin pore formation falls into this second 
class of mechanisms. Synergy between force exertion and perforin activity 
would reduce the amount of degranulation required for each killing event and 
thereby limit bystander damage resulting from excessive cytolytic secretion. It 
would also facilitate serial killing by enabling CTLs to reserve perforin and 
granzyme for other targets. We expect that other cytotoxic lymphocytes will 
also employ this strategy. 
Our results demonstrate that NMII is critical for force exertion at the IS. 
This is surprising given that myosin activity is dispensable for IS formation and 
only modestly affects synaptic architecture113–115. We also found that depletion 
of NMII reduced CTL-mediated cytotoxicity, implying that myosin-dependent 
forces contribute to mechanopotentiation during target cell killing. Although we 
favor this interpretation, it must be noted that CTLs lacking NMII also exhibit 
delayed centrosome polarization117. A partial polarity defect could affect 
cytotoxicity by altering the directionality of cytolytic secretion. Hence, at this 
stage we cannot attribute the killing phenotype of NMII-deficient cells solely to 
a defect in force exertion. 
Perforin pores drive target cell killing by inducing a membrane repair 
response that stimulates the uptake of additional perforin and granzymes57,58. 
Although the methods used in this study assessed the effects of cellular 
mechanics on initial pore formation, they did not address whether force might 
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also modulate membrane repair downstream. Membrane tension has been 
implicated in the regulation of both exo- and endocytosis in multiple cell 
types139. It is therefore quite plausible that CTL-induced distortions within the 
IS could influence membrane repair and in this manner control not only the 
initiation but also the progression of cytotoxicity. 
F-actin accumulates in the periphery of the IS and is depleted from the 
center, forming a stereotyped annular pattern107. Lytic granules cluster 
beneath the center of the F-actin ring, and it has been proposed that they 
release their contents primarily by fusing with the actin-free plasma membrane 
in this region14,134. Using a fluorescent probe for degranulation, we found that 
cytolytic secretory events are not enriched in the very center of the IS, but 
rather in an intermediate domain that overlaps with the region of strongest 
force exertion. In the canonical IS, this intermediate zone is occupied by the 
inner aspect of the F-actin ring and clusters of integrin; it therefore contains 
the adhesive and cytoskeletal machinery required to transmit force140. Super-
resolution imaging studies have demonstrated that this zone can also 
accommodate the formation of actin hypodense regions of plasma membrane 
suitable for vesicle fusion130,141. Accordingly, we favor a model in which 
degranulation occurs at the border between the central F-actin-depleted area 
and the peripheral F-actin ring. This would enable the CTL to balance the 
physical requirements of exocytosis with the benefits of synaptic 
mechanopotentiation. 
The striking spatiotemporal correlation we observed between lytic 
granule release and force exertion suggests that CTLs create local mechanical 
hotspots on the target cell surface that are particularly sensitive to perforin. 
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Although the fluid nature of lipid bilayers generally promotes rapid equilibration 
of applied force, local interactions with the cytoskeleton have been shown to 
generate inhomogeneities in tension139. The idea that physical 
inhomogeneities of this kind could be established within dynamic and strongly 
adhesive interfaces, such as the IS, is quite intriguing, and represents an 
interesting topic for future studies. 
The mechanical component of cytotoxicity could be particularly 
important in the context of anti-cancer immunity. Within solid tumors, cells tend 
to be stiffer because of enhanced cytoskeletal contractility and extracellular 
matrix rigidity142. Although increased stiffness would be expected to promote 
CTL-mediated killing, any advantage gained by the immune system would 
likely be overwhelmed by the tolerogenic signals that prevail within the tumor 
microenvironment143. During metastatic dissemination, however, cells from the 
tumor move away from this immunosuppressive milieu. In that regard, it is 
interesting to note that isolated cancer cells tend to be softer than their non-
transformed counterparts144–146. This deformability could enable them to 
resist immune-mediated attack when outside of the tumor microenvironment. 
The intricate cytoskeletal dynamics of lymphocyte synapses include 
both actin flows that propagate in the plane of the interface and filopodial 
protrusions that can deform the surface of the target cell70,108,109,147,148. As we 
work to define the functional relevance of these and other structures, it will be 
important to consider their capacity to transmit information physically during 
the effector phase of lymphocyte responses. Mechanical forces are well suited 
for rapid and highly compartmentalized signaling within cell-cell interfaces and 
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as such, they represent a valuable mode of intercellular communication in 
complex environments. 
2.4. Materials and Methods 
2.4.1. Mice 
The animal protocols used for this study were approved by the 
Institutional Animal Care and Use Committee of Memorial Sloan-Kettering 
Cancer Center. 
2.4.2. Cell culture and transductions 
CTLs were prepared by mixing T cells from OT-1 αβTCR transgenic 
mice (Taconic) with irradiated congenic splenocytes pulsed with 100 nM OVA 
and cultured in RPMI medium containing 10 % (vol/vol) FCS. Cells were 
supplemented with interleukin 2 (IL2, 30 IU/ml) after 24 h and were split as 
needed in RPMI containing IL-2. B16-F10 cells were maintained in DMEM 
containing 10 % (vol/vol) FCS, while RMA-s and EL4 cells were grown in 
RPMI containing 10 % (vol/vol) FCS. 
Expression constructs for shNT, shDock2, shPTEN, shMyH9, and 
pHluorinLamp1 have been described8,117,130. To prepare retrovirus, Phoenix E 
cells were transfected with expression vectors together with packaging 
plasmids using the calcium phosphate method. Ecotropic viral supernatants 
were collected after 48 hr at 37°C and added to OT-1 blasts 2 days after 
primary peptide stimulation. Mixtures were centrifuged at 1400 × g in the 
presence of polybrene (4 µg/ml) at 35°C. T cells were then split 1:3 in medium 
containing IL-2. 
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2.4.3. Pillar studies 
Micropillar coating and data acquisition. For coating, arrays were 
washed with ethanol and phosphate buffered saline (PBS) and then incubated 
in Alexa568-labeled streptavidin (20 µg/ml in PBS) at room temperature for at 
least two hours. After further washing in PBS, the arrays were incubated with 
biotinylated H2-Kb -OVA and ICAM-1 (each 20 µg/ml in PBS) for 2 hours at 
room temperature. The pillars were then washed into colorless RPMI 
containing 5% FCS (Imaging medium). Data acquisition was implemented 
using Metamorph software. For standard force quantification experiments 
(Figure 2.4), brightfield, Alexa488 (CTL), and Alexa568 (pillars) images were 
collected every 15 s. For degranulation experiments (Figure 2.12), brightfield, 
Alexa488 (degranulation), Alexa647 (CTL), and Alexa568 (pillars) images 
were collected every 20 s. Images were exported as tif files and aligned using 
a custom Matlab script. 
2.4.4. Micropillar deflection analysis 
Center of gravity (COG) projections of pillar deflections were 
determined by calculating the projection of each deflection along a line 
connecting the pillar to the COG of the CTL footprint. Degranulation events 
were identified as an abrupt increase in GFP fluorescence. To determine the 
DDP (Distance to Displaced Pillar) parameter for a degranulation event, 
average deflections were 2 determined for the time period beginning 40 s 
before degranulation and extending 120 s after. “Strongly deflected” pillars 
were then identified as pillars with mean deflections ≥ 0.75 × the mean 
deflection of the most strongly deflected pillar during this time frame. The 
distance between the degranulation position and the closest “strongly 
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deflected” pillar was defined as the DDP. DDP values for degranulation events 
were compared to null distributions generated by performing the DDP 
calculation for every position in the CTLarray interface at the time of 
degranulation. Paired analysis of degranulation DDPs and mean DDPs from 
null distributions was carried out using Prism (GraphPad). Radial shell 
analysis was performed by determining the position of relevant pillars and 
degranulation events along a segment beginning at the COG of the interface 
(assigned a value of 0) and ending at the edge of the interface (assigned a 
value of 10). The mechanical energy required for pillar deflections was 
calculated using the following expression (E = Fd/2), where E is the energy, F 
is the force, and d is the length of the deflection. 
2.4.5. Cytotoxicity assays 
RMA-s cells labeled with the membrane dye PKH26 (Sigma-Aldrich) 
were pulsed with varying concentrations of OVA and mixed 1:1 in 96-well 
plates with OT-1 CTLs. After 6 hr at 37° C, samples were treated with 2.5 mM 
EDTA to disrupt conjugate formation and specific lysis of PKH26+ target cells 
was assessed by flow cytometry as described149. 
B16-F10 cells were cultured overnight on fibronectin-coated hydrogels 
in the presence of 20 ng/ml IFNγ, which was included to induce upregulation 
of class I MHC. They were then loaded with 100 nM OVA for 1 hour and 
washed three times in lactate dehydrogenase (LDH) release assay medium 
(RPMI with 5% vol/vol FCS). OT-1 CTLs were added at various effector to 
target (E:T) ratios and incubated for 5 hr at 37° C in LDH medium. Target cell 
death was quantified with an LDH cytotoxicity assay kit (Clontech) using the 
manufacturer’s recommended protocol. All measurements were performed in 
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triplicate. To assess degranulation responses, CTLs were added to B16-F10 
cells at a 1:1 E:T ratio and incubated for 2 hr at 37° C in the presence of 
eFluor660 conjugated anti-Lamp1 antibody (1 µg/ml, Clone 1D4B, 
eBiosciences). Staining was quantified by flow cytometry. In staurosporine-
induced apoptosis assays, B16 cells cultured on fibronectin-coated hydrogels 
were treated with varying concentrations of 3 staurosporine, and lysis was 
quantified by LDH release after 17 h at 37 C. 
2.4.6. Perforin pore formation in microwells 
PDMS grids containing 50 × 50 × 50 µm wells were submerged in 
imaging medium and seeded with CFSE-labeled RMA-s cells that had been 
pulsed with 1 µM OVA. In general, individual wells contained one to three 
RMA-s cells; 100 µM PI (Life Technologies) was added to the medium 
to enable real-time visualization of perforated cells. Then, CTLs expressing 
shNT or shPTEN together with CFP were added and the cells imaged using a 
20× objective lens (Olympus) at 6-min intervals for 8 hr. Brightfield, GFP, CFP, 
and PI images were collected at each time point. Quantification was restricted 
to target cells forming synapses with only one T cell during the first 6 hr of the 
imaging experiment. All cells in this category were scored for the time of initial 
IS formation and also for the first appearance of PI signal above background. 
2.4.7. Micropipette preparation and calibration 
Tapered micropipettes were prepared by pulling borosilicate glass 
capillaries (1 mm OD, 0.78 mm ID, Harvard Apparatus) with a P-97 device 
(Sutter Instruments). A microforge (MF-200, WPI) was used to cut the bead 
micropipette and the rigid CTL micropipette at the desired diameters (typically 
1 µm and 3 µm, respectively). Another microforge (MF-900, Narishige) was 
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then used to introduce a 90° bend at the end of the bead micropipette. 45° 
angles were also introduced into the bodies of both pipettes to position their 
extremities orthogonal to the imaging plane during experiments. The bending 
stiffness k of the bead micropipette was measured by pushing its tip against 
the tip of a thicker micropipette of known stiffness. A single-axis piezo 
translation stage (Thorlabs) was used to move the bead micropipette in a 
sinusoidal fashion and the position of each tip was detected at 30Hz using a 
homemade Labview program (National Instruments). The observed ratio of 
pipette deflections was then used to deduce the stiffness of the bead 
micropipette (typically k = 0.1 nN/µm). 
2.4.8. Micropipette-Based Force Measurements 
Stimulatory beads were prepared by coating 6-µm diameter 
streptavidin-coated polystyrene particles (Spherotech) with biotinylated H2-Kb-
OVA and ICAM-1 (1 µg/ml each) for 2 hr in 20 mM HEPES pH 7.5, 150 mM 
NaCl, 2% w/v BSA. Micropipettes for stimulatory beads and CTLs were 
prepared from borosilicate glass capillaries (1 mm OD, 0.78 mm ID, Harvard 
Apparatus). Imaging was carried out in an open top, environmentally 
controlled chamber mounted on an inverted microscope (Nikon TE300) 
equipped with a 100× objective lens. The rigid CTL micropipette was attached 
to a motorized micromanipulator (MP285, Sutter Instruments) and the bead 
micropipette to manual micrometers (Thorlabs). Beads were aspirated into the 
tip of the calibrated micropipette by applying ∼6 kPa aspiration pressure using 
a syringe (typically 1 ml air volume depression). Two hundred pascals of 
pressure (applied using a water reservoir) was used to aspirate a CTL into the 
tip of the rigid pipette. Time-lapse recordings were started just before the CTL 
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was gently brought into contact with the bead. In general, 50 ms brightfield 
exposures were taken at 2-s intervals for 3–5 min using Micromanager 
software. The deflection of the flexible micropipette was determined by 
tracking the position of the bead using a customized ImageJ macro110. Bead 
position was determined with a precision of <60 nm, corresponding to a 
precision in force better than 6 pN for probe bending stiffness k = 0.1 nN/µm. 
2.4.9. Cellular perforation assay 
Twenty-four hours prior to imaging, B16-F10 cells were plated at 
104cells/100 µl/well in either fibronectin-coated 96-well plates (Costar) or in 96-
well flat-bottom plates coated with polyacrylamide hydrogels (Matrigen) 
and fibronectin. One hour prior to imaging, cells were transferred into C+ buffer 
HBSS (Hank’s balanced salt solution) with 10 mM HEPES pH 7.2, 4 mM 
CaCl2, 2 mM MgCl2, 0.4% BSA) containing Hoechst 33342 stain (1:2,000, 
Invitrogen). PI (100 µM final concentration) was added along 
with Blebbistatin (Sigma) or Latrunculin A (Sigma) as necessary. After 5 min, 
Hoechst and PI images were collected at 2-min intervals for 30 min using an 
inverted wide-field microscope (Zeiss Axiovert 200M, Metamorph acquisition 
software) fitted with a 5× objective lens (Zeiss). Dilutions of purified perforin in 
50 µl C− buffer (HBSS, 10 mM HEPES pH 7.2, 1 mM EGTA, 0.4% BSA) were 
added 4 min into the imaging run. To vary tonicity, hypertonic (+150 mM 
sucrose) or hypotonic (H2O instead of HBSS) C+ and C− buffers were used 
instead of isotonic C+ and C−. 
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2.4.10. Perforin purification and fibronectin coating for 
perforation assay 
Human perforin was purified from YT-Indy cells as described150, but 
using the following modified relaxation buffer: 100 mM KCl, 3.5 mM MgCl2, 10 
mM PIPES pH 6.8, 1.25 mM EGTA, and 1 mM ATP. Perforin is a metastable, 
hydrophobic molecule with a tendency to aggregate. The overall activity of 
each preparation varied considerably, and the activity of any one preparation 
changed over the course of a few hours. To circumvent this issue, we 
collected each experimental condition either right before or right after its 
associated control, and switched the order of data collection in repeat 
experiments. This enabled us to observe robust relative changes, despite the 
day-to-day variation in overall perforin activity. For coating, plastic wells were 
incubated with 10 µg/ml fibronectin (Calbiochem) for 1 hr at 37° C, and 
polyacrylamide hydrogels (Matrigen) were incubated with 10 µg/ml fibronectin 
for 30 min at room temperature. 
2.4.11. Lytic granule polarization 
OT-1 CTLs expressing shNT, shDock2, or shPTEN together with GFP 
were mixed 1:1 with EL4 thymoma cells that had been loaded with 1 µM OVA. 
After 10 min, cells were transferred into warm HBSS, attached to poly-D-
lysine-coated coverslips, and fixed with 4% paraformaldehyde. After washing 
with PBS and permeabilization with 0.2% Triton X-100 in PBS, cells were 
blocked with PBS + 10% normal goat serum and then incubated in blocking 
buffer containing antibodies against Lamp1 (eBioscience, clone 1D4B, 1:200 
dilution) and pericentrin (Abcam, rabbit polyclonal, 1:200 dilution) overnight at 
4° C. Cells were then washed in PBS and incubated in blocking buffer 
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containing Alexa594 labeled anti-Rat antibodies and Alexa647 labeled anti-
Rabbit antibodies (both 1:1000 dilution) for 2 hr at 4° C. After a final wash in 
PBS, Cells were mounted on glass slides and sealed. CTL-target cell 
conjugates were imaged using an inverted fluorescence microscope (Olympus 
IX-81) fitted with a 65× objective lens (Olympus). In addition to a brightfield 
image, z-stacks (1 µm increments, 20 µm total) of Alexa594, Alexa647, and 
GFP were collected for each field of view. Lytic granule polarization was 
quantified using projection images derived from the z-stack data. For each 
CTL, intensity thresholding was used to establish a mask encompassing the 
lytic granule compartment. Polarization of this mask toward the IS was then 
quantified by calculating a polarization index = (Distance between the IS and 
the center of gravity of the granule mask)/(Distance between the IS and the 
opposite side of the CTL). T-test analysis of the resulting distributions was 
performed in Prism. 
2.4.12. Immunoblot 
0.2-1 × 106 CTLs were lysed in ice cold buffer containing 10 mM 
TrisHCl, 5 mM EDTA, 1% NP-40, 0.5% sodium deoxycholate, and 0.15 M 
NaCl. Perforin expression was assessed using a rabbit polyclonal antibody 
(Cell Signaling). Actin served as a loading control (clone AC-15, Sigma). 
2.4.13. Ca2+ imaging 
CTLs were loaded with 5 µg/ml Fura-2AM and then added to glass or 
PDMS surfaces that had been coated with H2-Kb -OVA and ICAM-1. 
Stimulatory PDMS was prepared as described above and glass surfaces were 
coated using an established protocol149. Fura2 images using 340 nm and 380 
nm excitation were acquired every 30 seconds for 20–30 min with a 20× 
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objective lens (Olympus). Single cell Ca2+ responses were quantified by 
normalizing the Fura2 ratio of each cell using the last image before the initial 
rise in Ca2+. 
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CHAPTER 3: INSIGHTS INTO ADOPTIVE 
CELL THERAPIES FROM MODULATING 
PI3K IN A TRANSPLANTABLE MELANOMA 
MODEL 
3.1. Introduction 
For decades, there has been great interest in using the immune system 
to treat cancer. Recently, several pioneering strategies have emerged that 
have reinvigorated the field, especially with respect to the idea of ACTs as a 
way to treat cancer96,98. These treatments involve isolating a patient’s cells 
from peripheral blood and expanding them ex vivo. When the cells are being 
cultured ex vivo, they can be treated with various cytokine cocktails or 
transfected with various plasmids. Constructs of interest include ones to drive 
expression of an engineered receptor such as a CAR, which targets the T cell 
to attack cells expressing tumor antigens like CD19. These expanded cells are 
then transferred back into the patient where they attack the patient’s cancer.  
We wondered whether the shRNA targeting PTEN we had identified 
and characterized previously would be a viable way to increase the killing 
capacity of T cells in vivo and to improve ACTs. We hypothesized that 
increasing the cytotoxic potential of T cells used in ACT would increase the 
efficiency of ACT. We chose to examine ACT using a mouse melanoma 
model151,152. Surprisingly, we found that T cells expressing the shRNA 
targeting PTEN performed worse than control cells despite exhibiting 
increased cytotoxicity in vitro. We discovered that shPTEN T cells experienced 
reduced persistence in vivo that diminished their ability to form an anti-tumor 
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response and to control tumor growth. This provided us with an opportunity to 
examine how migration, survival, and proliferation contribute to persistence. 
We discovered that shPTEN CTLs have defects in migration and homeostatic 
proliferation, which contribute to reduced persistence relative to control CTLs. 
3.2. Results 
3.2.1. PTEN depletion increases cytotoxicity 
Even though PTEN depletion has been previously shown to enhance T 
cell cytotoxicity in vitro8,153, we wanted to demonstrate that the increase in 
cytotoxicity we observe with shPTEN CTLs was not due to an off-target effect 
of the shRNA. To do this, we isolated OT-1 T cells from a mouse expressing 
Cas9 in the Rosa26 locus and transduced them with a retroviral construct to 
express a gRNA targeting PTEN154. Complete deletion of PTEN was 
confirmed by Western Blot (Figure 3.1A). Next, we assessed the cytotoxic 
capacity of PTEN depleted cells, comparing cells that were treated with the 
shRNA and the gRNA. We found that both methods of deleting PTEN result in 
increased cytotoxicity relative to nontargeting control constructs (Figure 3.1B). 
This shows that the increase in cytotoxicity we observe is due to PTEN 
depletion and not off target effects of an shRNA.  
3.2.2. PTEN depletion reduces anti-tumor effect 
We next assessed the effect shPTEN CTLs had on tumor rejection using a 
transplantable B16-OVA melanoma model to evaluate ACT151,152. A schematic 
of the experimental outline is shown in 3.2A. Mice were implanted with 2x105 
B16-OVA cells subcutaneously (s.c.) and small tumors were allowed to 
develop. After 7-9 days, the mice were sublethally irradiated with 600cGy to 
establish a lymphopenic environment. The following day, 1x106 CTLs 
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transduced with either a control shNT or shPTEN vector were transferred to 
the mice by i.v. injection. The tumors were then monitored over the next few 
weeks and measured with calipers. We observed an impaired anti-tumor 
response in mice that received shPTEN CTLs relative to control mice (Figure 
3.2B).  This was unexpected as we thought the mice receiving shPTEN CTLs 
would experience an enhanced anti-tumor effect given their increased 
cytotoxicity in vitro (Figure 3.1B). This provided us with an intriguing 
opportunity to study the components of ACT necessary for anti-tumor effects 
that are independent of cytotoxicity.  
 
  
Figure 3.1 PTEN depletion enhancing cytotoxicity 
(A) PTEN was depleted using CRISPR/Cas9 and knockout was confirmed by 
Western Blot.(B) We observed a similar increase in cytotoxicity when we 
deleted PTEN using CRISPR/Cas9 as shRNA. The provided Western Blot was 
cropped from a single membrane to display the relevant bands. Error bars 
denote SEM. 
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3.2.3. PTEN deficient T cells fail to persist in vivo 
To understand the diminished anti-tumor effect observed for mice 
receiving shPTEN CTLs, we conducted experiments to monitor persistence of 
the cells. We adapted our experimental setup to utilize congenic recipients. 
This provided us with a way to differentiate host cells from transferred cells. 
We transferred a 50:50 mixture of congenically marked CD45.1/2 CTLs 
expressing shPTEN and shNT into a tumor bearing recipient mice expressing 
CD45.2 (Figure 3.3A).  We distinguished shPTEN and shNT cells by marking 
them with different fluorescent reporters. 
  
Figure 3.2 PTEN deletion results in reduced anti-tumor effect in vivo 
(A) Schematic showing experimental procedure where B16-OVA cells were 
implanted and OT-I cells were transferred after 9 days. (B) Tumor growth was 
measured over 15 days post transfer of T cells transduced to express the 
indicated shRNA. Error bars denote SEM.  
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Figure 3.3 PTEN depleted T cells have reduced persistence in vivo 
(A) Schematic showing the experimental procedure where a mixture of 
CD45.1/2 expressing T cells were transferred into a tumor bearing CD45.2 
recipient. (B) Organs were harvested at the indicated times and analyzed for 
the presence of transferred cells. The draining lymph node (dLN), non-draining 
lymph  node (ndLN), and mesenteric lymph node (mLN) were also analyzed. 
(C) Additional organs were analyzed for the presence of shPTEN T cells after 
3 days. Error bars denote SEM. 
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We found that that within 6 days after transfer there was a reduced ratio 
of shPTEN cells to shNT control cells in all organs (Figure 3.3B). PTEN 
depleted T cells seemed to stay in the lungs and liver temporarily. However, 
the shPTEN cells were not present in the secondary lymphoid organs 
including the spleen and various lymph nodes (Figure 3.3B).  We assessed 
whether the shPTEN cells could be homing to other tissues and examined the 
gut, bone marrow, and brain (Figure 3.3C). The shPTEN cells found in these 
tissues were at similar ratios to control cells as previously found (Figure 3.3B). 
Hence, depletion of PTEN induced a persistence defect after adoptive transfer 
into lymphopenic recipients. 
3.2.4. Persistence defect not due to shRNA specificity 
We wanted to test whether the persistence phenotype we observed for 
CTLs expressing shPTEN could be an off-target effect of the shRNA. To 
address this, we conducted co-transfer experiments using multiple methods of 
depleting PTEN. We depleted PTEN using the CRISPR/Cas9 system and 
performed a co-transfer experiment with a nontargeting gRNA. We also 
examined whether the phenomenon we had only observed in CD8+ T cells 
could also occur in CD4+ T cells by transducing polyclonal T cells isolated from 
a mouse expressing the PTENfl/fl allele with a retroviral Cre155. We observed 
the same loss of CTLs in mice that received Cas9/gRNA and shRNA treated 
cells (Figure 3.4A). Furthermore, we observed the same effect when we 
adoptively transferred polyclonal T cells isolated from PTENfl/fl mice and 
transduced with Cre or an empty vector control into a lymphopenic recipient 
mouse (Figure 3.4B). Interestingly, we found that CD4+ T cells seemed to also 
be affected but to a lesser degree than CD8+ T cells. This suggested to us that 
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the loss of PTEN deficient cells we were observing was the direct result of 
PTEN loss and not an off-target effect. 
These observations agree with previous work demonstrating that T cells 
with a constitutively active AKT had a defect in persistence following LCMV 
infection156. This is also consistent with work showing that enhancing PI3K 
signaling in thymocytes isolated from Lck-Cre PTENfl/fl mice reduces their 
persistence in a PDK1 dependent manner157. Together, these results 
demonstrate that modulating PI3K signaling has detrimental effects on T cell 
persistence in vivo. 
Persistence of shPTEN cells in vivo is reflective of several factors 
including survival, migration, and proliferation. As adoptively transferred cells 
Figure 3.4 Loss of PTEN depleted cells is not due to shRNA 
Co-transfer experiments confirmed that depleting PTEN by CRISPR/Cas9 (A) 
and by transducing PTENfl/fl cells with Cre (B) phenocopy loss of shPTEN 
cells(A). Error bars denote SEM. 
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migrate through secondary lymphoid organs, they are exposed to survival 
signals158. If transfer occurs into a lymphopenic host, the lymphocytes will 
undergo homeostatic expansion, which can further obfuscate persistence. In 
order to properly understand the persistence defect of shPTEN T cells, we 
sought to disentangle these components and evaluate them separately. 
3.2.5. PTEN deficient T cells have a defect in migration 
We wanted to assess whether the defect in persistence we observed 
could be the result of a trafficking defect. We designed a series of short-term 
migration experiments to assess the ability of shPTEN CTLs to migrate in vivo. 
We transferred a 50:50 mixture of shPTEN and shNT cells as before (Figure 
3.3A). Tissues were processed and analyzed 2 hours post transfer. At this 
time point, most of the shNT and shPTEN cells were isolated from the lungs 
and liver.  An appreciable number of cells could also be found in the blood, 
spleen, lymph nodes, and tumor, however, enabling comparative analysis.  
The ratio of shPTEN to shNT cells was reduced within two hours after transfer 
(Figure 3.5A). The shPTEN T cells were unable to migrate to secondary 
lymphoid organs (Figure 3.5A-D). shPTEN T cells were mainly found in the 
liver and lungs, but did not persist in these tissues long enough and were not 
present after 6 days (Figure 3.3B). Between the 2 hour and 22 hour time point, 
there was a significant loss of shPTEN cells in the blood and an increase in 
the number of cells in the liver (Figure 3.5A-D). There was also an increase in 
the number of shPTEN cells in the spleen at 22 hours even though the ratio is 
unchanged. These data suggest that PTEN deficient cells have a defect in 
migration in vivo.  
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3.2.6. PTEN deficient T cells have reduced expression of 
trafficking receptors 
We examined the PI3K/AKT signaling pathway to identify proteins that 
might be differentially expressed in PTEN deficient T cells. We identified the 
transcription factor KLF2, downstream of mTORC1 and FOXO1, as a protein 
that could contribute to a migration defect (Figure 3.6A). KLF2 plays an 
important role in regulating expression of CCR7, S1PR1, and CD62L29. We 
found that shPTEN CTLs expressed reduced levels of CD62L (Figure 3.6B-C). 
We also found that shPTEN CTLs expressed reduced levels of IL-7Rα (Figure  
Figure 3.5 PTEN deficient cells have migration defect 
(A-B) A short term migration experiment was conducted and organs were 
harvested and processed 2 hours after T cell transfer. The normalized ratio for 
shPTEN to shNT cells is given (A) and the number of cells collectd from each 
organ (B). Mice were also analyzed 22 hours after transfer (C-D). Lymph 
nodes (LN) were pooled and analyzed. Error bars denote SEM.  
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Figure 3.6 Enhancing PI3K signaling disrupts expression of key 
receptors 
(A) Diagram of PI3K signaling showing the proteins that are disrupted by 
depleting PTEN. (B) CD62L expression was reduced on shPTEN T cells. (C) 
CD62L and IL-7Rα was increased by treating cells with 2ng/mL IL-15 and 2nM 
rapamycin (R). (D) Expression of KLF2, S1PR1, and CCR7 was assessed by 
qPCR and found to be reduced in shPTEN CTLs. 
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3.6C). Furthermore, we found that the expression of KLF2 was reduced by 
qPCR.  We also observed reduced expression of CCR7 and S1PR1 in 
shPTEN CTLs by real time polymerase chain reaction (RT-PCR) (Figure 
3.6D). These results agree with previous data implicating PI3K signaling in T 
cell migration9,157. However, the observation that shPTEN cells have a defect 
in migration does not rule out other defects that might contribute to defective 
persistence.  
3.2.7. PTEN deficient T cells have increased cell survival in 
vitro 
Previous research has identified PTEN as a tumor suppressor as its 
loss promotes increased cell growth and proliferation159,160. We hypothesized 
that PTEN deficiency in T cells would drive a similar increase in cell survival 
and proliferation through PI3K and AKT signaling. However, T cell survival in 
vivo and homeostatic proliferation are driven by IL-7 and IL-15161. We found 
that IL-7Rα was downregulated on shPTEN CTLs (Figure 3.6C). We 
wondered whether this would effect the survival of shPTEN T cells in vivo 
where they depend on IL-7. We also wondered whether the increase in cell 
survival and proliferation associated with PTEN loss would occur in T cells 
moving from a high nutrient environment in vitro to a low nutrient environment 
in vivo. To assess these possibilities, we designed a survival assay to monitor 
T cell survival in low nutrient conditions. To understand how cytokine signaling 
could impact cell survival in low nutrient conditions, we incorporated a variety 
of cytokine conditions into the assay. We monitored survival after 1 and 2 days 
in the presence of 30 IU/mL IL-2, 1ng/mL IL-7, and 10ng/mL IL-7. As a control, 
we also monitored survival in the absence of cytokines (Figure 3.7A-D). PTEN  
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Figure 3.7 PTEN Deficient cells have similar or increased survival relative 
to control T cells 
(A-D)  CTLs transduced with shPTEN or shNT shRNAs were incubated for 1 
or 2 days with the media with the indicated nutrients removed or present. Error 
bars denote SEM. 
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deficient cells were found to have the same or increased survival in every 
condition measured. Thus, even though shPTEN T cells have reduced 
expression of IL-7Rα, there is sufficient expression for an IL-7 dependent 
increase survival relative to the no cytokine condition. However, the lack of 
evidence supporting a cell survival defect in vitro does not rule out the 
possibility that PTEN deficient T cells have a survival defect in vivo. 
3.2.8. Enhancing survival of PTEN deficient T cells does not 
rescue persistence in vivo 
To investigate the relationship between T cell survival and in vivo 
persistence, we attempted to perturb cell survival in vivo. We chose to do this 
by designing a construct to over express Bcl-2 together with the mApple 
fluorescent reporter (Figure 3.8A). Over expression of this construct 
significantly increased survival of T cells cultured without cytokines for 3 days 
in vitro (Figure 3.8B). Expression of Bcl-2 was also confirmed by Western Blot 
(Figure 3.8C).  
We designed an experiment to test the effect of increased survival on T 
cell persistence in vivo. The previous co-transfer experimental protocol (Figure 
3.2A) was adapted to form three groups of mice. Group A was to measure the 
effect that increased survival had on persistence (Figure 3.8D). Group B was a 
control showing that PTEN deficiency results in a persistence defect. Group C 
assessed whether increasing survival was able to rescue persistence in PTEN 
deficient T cells (Figure 3.8D). We found that Bcl-2 overexpression resulted in 
a marginal improvement to persistence in the blood, liver, and lung (Figure 
3.8E-G). However, it did not boost persistence in the tumor, which confirms 
the existence of the migration defect previously identified (Figure 3.8H, also  
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Figure 3.8 Increasing survival of PTEN deficient cells has modest effect 
on persistence 
(A) Schematic for the BCL-2 over expression construct that was used in these 
experiments. (B) BCL-2 over expression enhanced the survival of T cells 
transduced with the indicated constructs. Survival was evaluated after 3 days 
without cytokines. (C) BCL-2 over expression was confirmed by Western Blot. 
(D) Schematic showing the three groups A, B, and C that were transferred into 
tumor bearing CD45.2 mice. (E-H) Normalized ratios of each group after 6 
days. 
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Figure 3.5A-D). There was a boost in the number of transferred cells 
circulating in the blood, but this did not quite match the boost in circulating 
cells observed for the control cells overexpressing Bcl-2 (Figure 3.8E). This 
suggests that any survival defect in shPTEN T cells is likely minor and not 
playing a predominant role in their persistence defect. 
3.2.9. PTEN deficient T cells have defect in homeostatic 
proliferation 
The transplantable model of melanoma used throughout this work relies 
on a 600 cGy dose of radiation to create a lymphopenic environment for the 
transferred cells to proliferate. Homeostatic proliferation is driven by IL-7 and 
IL-15161, and PTEN deficient CTLs have reduced levels of IL-7Rα.  
Accordingly, we hypothesized that PTEN depletion impairs homeostatic 
proliferation, leading to defective persistence. To examine the role of 
proliferation on persistence, we compared sublethally irradiated mice with wild-
type (WT) mice. We also examined mice that were double knockouts for 
recombination-activating gene (RAG) and the common gamma chain receptor 
(RAG-/- γC-/-) mice, which are very lymphopenic and lack B, T, and NK cells162. 
We adapted our previous experimental setup to examine the role of 
proliferation by harvesting organs after 4 days. We found that WT mice had 
similar levels of transferred cells in the spleen and lungs after 4 days (Figure 
3.9A). The ratio of shPTEN to shNT cells in the blood was reduced in both 
sublethally irradiated mice and RAG-/-  γC-/- mice relative to WT mice (Figure 
3.9A). There was also a dramatic reduction in the ratio of shPTEN to shNT 
cells in the spleen and lung of the lymphopenic mice compared with WT mice. 
We observed an increase in the ratio of shPTEN to shNT cells in the liver in  
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Figure 3.9 PTEN deficient CTLs have defect in proliferation 
(A) T cells expressing either shNT or shPTEN shRNAs were transferred into 
WT, sublethally irradiated (600 cGy), or RAG-/- γC-/- double knokckout tumor 
bearing mice. After 4 days, the normalized ratio was calculated for the cells 
present in the indicated  organs. (B) Proliferation was assessed by dilution of 
CellTrace Violet on day 4 post transfer. Error bars denote SEM. 
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non-lymphopenic mice (Figure 3.9A). This was not surprising as we have 
already shown that PTEN depletion results a migration defect that enhances T 
cells ‘propensity to traffic to the liver over secondary lymphoid organs. 
However, all groups of mice had reduced ratios of shPTEN cells to shNT cells 
in the tumor (Figure 3.9A). This further reinforces our previous observation 
that shPTEN cells are unable to properly migrate in vivo. In the absence of 
proliferation, there are reduced numbers of shPTEN cells in the tumor relative 
to shNT control cells. These results indicate that by removing the homeostatic 
proliferation component of persistence we rescued the persistence of shPTEN 
cells in a subset of organs (lung, liver, and spleen). This demonstrates that 
part of the problem shPTEN T cells have persisting in vivo results from a 
defect in homeostatic proliferation.  
To assess whether PTEN depleted cells undergo reduced levels of 
proliferation, we stained a mixture of shPTEN and shNT T cells with a 
fluorescent dye and monitored dilution of the dye after 4 days in vivo. We 
found that the cells transferred into WT mice underwent almost no proliferation 
in vivo as expected (Figure 3.9B). We saw that shPTEN T cells transferred 
into mice treated with 600 cGy of radiation underwent reduced proliferation in 
the spleen, liver, and lung. Control T cells transferred into RAG-/- γC-/- mice 
underwent robust homeostatic proliferation but the shPTEN T cells had 
reduced levels of proliferation in the blood, spleen, liver, and lung. This 
suggests that PTEN deficient cells have a reduced ability to undergo 
homeostatic proliferation, which could be due to decreased expression of IL-
7Rα.  
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It is important to note that there are similar levels of proliferation for 
shPTEN and shNT cells in the tumor of WT as in the spleen (Figure 3.9B). 
This is interesting because the cells in the tumor are exposed to antigen, 
which promotes antigen driven proliferation. T cells in the spleen are not 
exposed to antigen and thus are only undergoing homeostatic proliferation. 
Cells isolated from the tumors of lymphopenic mice were found to have 
undergone proliferation (Figure 3.9B). This demonstrates that homeostatic 
proliferation plays an important role in ACT and suggests that tumor-infiltrating 
lymphocytes may undergo homeostatic proliferation before entering the tumor. 
This suggests that while antigen driven proliferation is important in the tumor 
and likely driving the anti-tumor response, homeostatic proliferation may play a 
critical role prior to antigen driven proliferation. This is an interesting 
observation and supports the idea that creating a lymphopenic environment is 
crucial component for ACT. 
3.2.10. PTEN deficient T cells experience mild proliferation 
defect in vitro 
In order to establish the role of reduced IL-7Rα expression in the 
homeostatic proliferation defect, we attempted to recapitulate the proliferation 
phenotype in vitro using recombinant cytokines. We cultured a mixture of 
shPTEN and shNT transduced T cells under a variety of conditions and 
monitored proliferation. We found that activating T cells with CD3/CD28 
dynabeads induced robust proliferation, but there was no difference between 
shPTEN and shNT cells (Figure 3.10). This is consistent with our hypothesis 
that the defect in proliferation observed in vivo stems from reduced level of IL-
7Rα effecting IL-7 signaling and homeostatic proliferation. Interestingly, PTEN  
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Figure 3.10 PTEN deficient CTLs have proliferation defect in vitro 
T cells transduced to express shNT or shPTEN were stained with CellTrace 
Violet and proliferation was assessed after the indicated number of days. 
CD3/CD28 stimulation was performed with dynabeads. IL-2 was used at 
30IU/mL. IL-7 and IL-15 were used at 5ng/mL. The mixture of IL-7 and IL-15 
contained 5ng/mL of each cytokine. 
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deficient T cells exhibited a modest proliferation defect with IL-2, IL-7, IL-15 
and a mixture of IL-7 and IL-15 (Figure 3.10). These defects in proliferation 
were milder that the defects observed in vivo. This suggests that the 
environment for promoting homeostatic proliferation in vivo is more complex 
than our in vitro environment and that we were not able to fully reconstitute it. 
Hence, more research is needed to fully implicate decreased expression of IL-
7Rα as the cause for reduced homeostatic expansion of shPTEN CTLs. 
3.3. Discussion 
The goal of this work was to examine whether we could apply our 
knowledge of cytotoxicity to improve ACTs. While we have not identified a way 
to harness the increased cytotoxicity of shPTEN CTLs, we have learned a 
significant amount about the necessary components of successful ACTs. We 
have shown that PTEN depletion reduces T cell anti-tumor effects in a 
transplantable model (Figure 3.2B). Furthermore, we showed that this is due 
to a loss of shPTEN T cells relative to control cells (Figure 3.3B). We 
examined the possible causes for this loss of shPTEN cells and discovered 
these cells display multiple defects that limit their utility in vivo. 
First, shPTEN T cells have a defect in migration that is associated with 
reduced expression of KLF2, which likely stems from increased PI3K/AKT 
signaling (Figure 3.6A). We believe that this results in reduced levels of 
CD62L, CCR7, and S1PR1 (Figure 3.6C-D), which causes the migration 
defect experienced by PTEN deficient cells. 
In addition, shPTEN T cells have a defect in homeostatic proliferation 
(Figure 9B). We suspect this stems from reduced expression of IL-7Rα due to 
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increased AKT signaling, which increases the pool of phospho-FOXO1 (Figure 
3.6A). This reduction in IL-7Rα expression does not impair IL-7 dependent 
survival of T cells in vitro, but seems to be sufficient to result in a significant 
defect in homeostatic proliferation in vivo. To confirm that the defect in 
homeostatic proliferation results from decreased levels of IL-7Rα, future work 
will investigate whether T cells lacking IL-7Rα phenocopy the PTEN 
deficiency. 
Over expression of Bcl-2 robustly blocks cell death in vitro (Figure 
3.8C), but only provides a slight improvement to the number of shPTEN cells 
migrating to the tumor. Furthermore, there is only a slight improvement in the 
number of cells in the blood, suggesting that something other than cell death 
is driving the apparent loss of shPTEN cells. These observations suggest that 
any defect in the survival of shPTEN T cells in vivo appears to be secondary to 
the defects in trafficking and proliferation. 
Subcutaneous tumor models require lymphocytes to undergo extensive 
migration to travel from the circulatory system to the secondary lymphoid 
organs and to the tumor. We found that CTLs expressing shPTEN had defects 
in migration that resulted in reduced ability of the cells to migrate to the tumor. 
This limited our ability to assess whether PTEN deficiency increases 
cytotoxicity in vivo. In order to demonstrate this, it may be necessary to 
examine shPTEN CTLs in a different tumor model. A model of lung or liver 
cancer may be better suited for evaluating the cytotoxicity of shPTEN T cells 
since they are capable of migrating to and surviving in the lung and liver. 
Another possible way to avoid the trafficking defects of shPTEN T cells is to 
perform on an intratumoral injection of T cells. While this is a technically 
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difficult procedure, it would circumvent the trafficking issues observed in the 
melanoma model. These avenues are worth considering as we examine ways 
to improve ACT using PTEN deficiency.  
The other issue with the model we used is that it relies on homeostatic 
proliferation to expand the adoptively transferred cells in order to generate an 
anti-tumor effect. When shPTEN cells were transferred into non-lymphopenic 
mice, they were able to persist at the same level as control cells in the spleen, 
liver, and lung even though they had reduced levels in the blood. It is worth 
considering whether shPTEN cells could provide increased survival in a tumor 
model that did not rely on homeostatic proliferation.  
In order to mitigate some of the negative side effects of PTEN 
deficiency, we examined whether we could reduce PI3K signaling with an 
inhibitor. We chose to use the AKT inhibitor A-443654 because previous work 
had demonstrated its ability to alter AKT signaling in vivo156. We pretreated 
mice with A-443654 before adoptively transferring T cells. However, treatment 
with A-443654 was unable to rescue the persistence of the transferred cells 
(data not shown). We also tried treating T cells in vitro prior to transfer with the 
AKT inhibitor ab142088. T cells were highly sensitive to this inhibitor and it 
was quite toxic (data not shown). The cells that survived the treatment had 
increased expression of CD62L but it is unclear how long this expression 
would have remained after transfer into mice. Nonetheless, it may be possible 
to boost the duration of effect by treating mice with different AKT inhibitors or 
by combining it with preconditioning the CTLs. 
   
111 
 
Another possible way to mitigate the negative side effects of enhanced 
PI3K/AKT signaling is by treating mice with rapamycin. Rapamycin is highly 
specific inhibitor for mTOR159. Pretreating mice with rapamycin might be able 
to reduce mTOR signaling enough to restore KLF2 and FOXO1 expression in 
the transferred cells. Rapamycin has been shown to enhance the formation of 
memory CD8+ T cells in response to an LCMV infection163. Modulating mTOR 
signaling with rapamycin may be a better way forward than treating mice with 
AKT inhibitors. It is also worth considering a combination approach whereby 
CTLs are pretreated with IL-15 and rapamycin and transferred into mice that 
are subsequently treated with rapamycin. Accordingly, we wondered whether 
we could apply combined rapamycin-IL15 treatment to increase the level of 
trafficking proteins to resolve the migration defect caused by enhanced PI3K 
signaling. Treating shPTEN and shNT CTLs with IL-15 and rapamycin 
increased the level of CD62L and IL-7Rα (data not shown). However, 
pretreating shPTEN CTLs with rapamycin and IL-15 was unable to improve 
persistence after 6 days (data not shown).  The mice were not treated with 
rapamycin and IL-15 after ACT, however, and it is possible that levels of 
CD62L And IL7R reverted during this time. Hence, more research is needed to 
fully examine this strategy as a way to fix the persistence defect.  
Another possible way to mitigate the effects of enhanced PI3K/AKT 
signaling is by increasing IL-7 or IL-15 signaling to improve homeostatic 
proliferation. This could be achieved by treating mice with lipopolysaccharides 
(LPS) or polyinosinic:polycytidylic acid (poly(I:C)). LPS and poly(I:C) stimulate 
IL-15 production by APCs through toll-like receptor 3 (TLR3)161,164. Treating 
with poly(I:C) may be more impactful as it has been shown to stimulate 
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hepatocytes to produce IL-7165. Enhancing production of IL-7 by hepatocytes 
could boost IL-7 signaling in PTEN deficient T cells, which we have shown 
have a tendency to reside in the liver. However, it is conceivable that the 
expression of IL-7Rα is sufficiently low to make it the limiting factor in IL-7 
signaling. In this case increasing the levels of IL-7 will be unable to restore IL-
7 signaling. 
Another way to enhance IL-7 signaling is to over express of IL-7Rα. 
This could rescue enough IL-7 signaling to restore homeostatic proliferation. It 
is also worth considering over expression of FOXO1 or a constitutively active 
FOXO1 to achieve this. This is more complicated, however, than over 
expressing IL-7Rα as FOXO1 signaling is important for many cellular process 
and could generate unanticipated consequences. FOXO1 is downstream of 
AKT and mTOR, but it also regulates genes that modulate the activity of AKT 
and mTOR166. This makes understanding the consequences of increased 
PI3K/AKT coupled with increased FOXO1 activity hard to predict. 
Furthermore, expression of a constitutively active mutant of FOXO1 in T cells 
has been shown to decrease tumor infiltration, which is already a problem for 
shPTEN CTLs167.  
Our studies of shPTEN T cells have highlighted the importance of T cell 
trafficking and homeostatic proliferation in the B16-OVA melanoma model of 
ACT. This work also suggests that while examining cytotoxicity in vitro can 
provide mechanistic insight, it may not be the best way to improve ACTs. 
Improving ACT with T cell screens assessing tumor infiltration, migration, and 
tumor growth may be more impactful than studies optimizing for cytotoxicity in 
vitro. 
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3.4. Materials and methods 
3.4.1. Mice 
The animal protocols used for this study were approved by the 
Institutional Animal Care and Use Committee of Memorial Sloan-Kettering 
Cancer Center. For in vivo experiments, C57BL/6J mice were purchased from 
Jackson Laboratories (stock #000664) at 6-8 weeks old. For experiments 
requiring congenic mice, B6.SJL-PtprcaPepcb/BoyJ mice were purchased from 
Jackson Laboratory (stock #002014). For experiments utilizing gRNAs, OT-1 
mice (Taconic) were crossed to Rosa26-Cas9 knockin mice 
(Gt(ROSA)26Sortm1.1(CAG-cas9*,-EGFP)Fezh/J, stock #024858)154. PTENfl/fl 
mice were purchased from Jackson Laboratories (stock #006440)155. RAG-/- 
γC-/- mice were purchased from Taconic Farms (stock #: 4111). 
3.4.2. In vivo tumor experiments 
B16-OVA cells were a gift from Jedd Wolchok. The cells were grown for 
at least 2 passages before they were counted, washed into PBS, and 
transferred s.c. to mice. The tumors were allowed to grow for 7-9 days before 
the mice were exposed to a sublethal dose of irradiation (600cGy). The 
following day, CTLs were transferred into the mice i.v. by retro-orbital injection. 
The tumor volume was calculated as 𝑉 = !!!!! . Measurements were performed 
with a caliper. 
3.4.3. Lymphocyte isolation from tissues 
Lung, liver, tumor, gut, and brain tissues were prepared by mechanical 
disruption followed by 40 min treatment with collagenase (Sigma, C5138) at 
1mg/mL in Hanks Buffered Salt Solution with calcium and magnesium. The 
tissues were washed filtered through 70 µm filters and subsequently layered in 
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a 44% and 66% percoll gradient (Sigma). The percoll gradient was performed 
by centrifuging at 3000 rpm for 30 minutes without the brake. The cells were 
collected from the interface and analyzed by flow cytometry. 
3.4.4. Flow cytometry and staining 
All flow cytometry was performed on a BD LSR II (Becton Dickinson). 
Antibodies used were purchased from Tonbo Biosciences, Biolgend, 
eBiosciences, and BD. The gating strategy used to detect cells that were 
transferred in vivo consisted of gating on single lymphocytes, CD3+ CD8+ 
double positive cells, and then the appropriate congenic marker. In 
experiments utilizing only one congenic in a co-transfer, GFP was used with 
either cyan fluorescent protein or mApple to distinguish the populations of 
cells. The ratio of shPTEN to shNT cells was calculated and then normalized 
by the ratio of the cells that were transferred into mice. 
The clones for antibodies used are as follows: CD127/IL-7Rα (A7R34), 
CD62L (MEL-14), CD3ε (145-2C11), CD8α (53-6.7), CD4 (RM4-5), CD45.1 
(A20), and CD45.2 (104). Cells were stained at room temperature for at least 
15 minutes in FACs buffer. Cells were stained with CellTrace Violet (Life 
Technologies) according to the manufacturers directions. 
3.4.5. Cloning 
The Bcl-2 over expression construct was generated from mouse cDNA 
was generated by PCR using the primers P2A-BCL2-fw (5’- 
AGAACCCAGGCCCTATGGCGCAAGCC -3’) and BglII-BCL2-rev (5’- 
AAAAAAGATCTTCACTTGTGGCCCAGGTATGCACC -3’). A P2A site was 
added to mApple-N1 by PCR with the oligos: NotI-mApple-fw (5’- 
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TTTTTGCGGCCGCATGGTGAGC -3’), P2A-rev (5’- 
GGCTTGCGCCATAGGGCCTGGGTTCT -3’), and the P2A fragment (5’- 
GGAAGTGGTGCAACAAATTTCAGCCTTCTCAAACAAGCAGGTGATGTCGA
GGAGAACCCAGGCCCT -3’). mApple-N1 was a gift from Michael Davidson 
(Addgene plasmid # 54567).168 The final product was cloned into an empty 
MSCV vector containing a Zeocin resistance cassette using NotI and BglII. A 
control was also generated of mApple in the same vector. The PCR was 
performed using Phusion (NEB) and according to the manufacturers protocol. 
The constructs were confirmed by sequencing (Genewiz). 
Expression constructs for shNT and shPTEN that were previously 
described were moved the LEPG vector with a miR30E backbone8,117,169. The 
miR30E vector was a gift from Scott Lowe. The primers to move the hairpins 
from their original vector to the miR30E vector were miRE-Xho-fw (5’- 
TGAACTCGAGAAGGTATAT TGCTGTTGACAGTGAGCG -3’) and miRE-
EcoOligo-rev (5’-TCTCGAATTCT AGCCCCTTGAAGTCCGAGGCAGTAGGC 
-3’)169. The mApple fluorescent protein as cloned into the miR30E vector by 
performing PCR to assemble an IRES-mApple fragment with PacI and ApaI 
cut sites. The mApple fragment was generated using primers IRES-mApple-F 
(5’- TGGCCACAACCATGGTGAGCAAG -3’) and (5’- 
ATAATTCTTAATTAATTCACTTGTACAGCTCGTCCATG -3’). The IRES 
fragment was generated using ApaI-IRES-F (5’- 
AATGTGAGGGCCCGGAAACC -3’) and IRES-mApple-R (5’ 
CCATGGTTGTGGCCATATTATCATCG -3’). PCR was performed to combine 
these two fragments and the product was cloned into the miR30E vector using 
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the PacI and ApaI cutsites (NEB). Proper insertion of mApple was confirmed 
by sequencing (Genewiz). 
gRNAs to knokckout PTEN were generated using previously published 
methods170. The selected gRNA was made by annealing oligo-1 (5’- 
CACCGaacttgtcctcccgccgcgt -3’) and (5’- AAACacgcggcgggaggacaagttC -3’) 
and cloned into the lenti-Guide-Puro vector according to published 
protocols171,172. The portion of the construct containing the gRNA was then 
amplified by PCR using LMP BamHI F2 (5’- 
TTTTTGGATCCTAGTAGGAGGCTTGGTAG -3’) and LMP EcoRI R2 (5’- 
TTTTTGAATTCTGTCTACTATTCTTTCCC -3’). This fragment was digested 
with BamHI and EcoRI (NEB) and ligated into the miR30E vector digested with 
EcoRI and BglII (NEB). The presence of the gRNA was confirmed by 
sequencing (Genewiz). 
3.4.6. Cell culture and transductions 
CTLs were prepared by mixing T cells from OT-1 αβTCR transgenic 
mice (Taconic) with irradiated congenic splenocytes pulsed with 100nM OVA 
and cultured in RPMI medium containing 10 % (vol/vol) FCS. Polyclonal T 
cells were activated using CD3/CD28 Dynabeads (Life Technologies). 
Lymphocytes were isolated from the spleen, counted, and incubated with 
dynabeads at a 1:1 ratio. Cells were supplemented with interleukin 2 (IL2, 30 
IU/ml) after 24 h and were split as needed in RPMI containing IL-2. B16-OVA 
cells were maintained in RPMI containing 10 % (vol/vol) FCS with 50ug/mL 
G418, while RMA-s cells were grown in RPMI containing 10 % (vol/vol) FCS. 
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To prepare retrovirus, Phoenix E cells were transfected with expression 
vectors together with packaging plasmids using the calcium phosphate 
method. Ecotropic viral supernatants were collected after 48 hr at 37°C and 
added to OT-1 blasts 2 days after primary peptide stimulation. Mixtures were 
centrifuged at 1400 × g in the presence of polybrene (4 µg/ml) at 35°C. T cells 
were then split 1:3 in medium containing IL-2. Selection was added 24 hours 
after transduction. Puromycin was used at 5-10ug/mL and Zeocin was used at 
100ug/mL (Life Technologies). 
Restimulation experiments were conducted with CD3/CD28 dynabeads 
(Life Technologies) at a 1:1 ratio. For other experiments, cells were treated in 
2ng/mL mouse IL-15 (eBioscience), 5ng/mL mouse IL-7 (eBioscience), and 
2nM rapamycin (EMD Millipore) overnight at 37°C. 
For in vitro experiments involving AKT inhibitors, we used The AKT1/2 
inhibitor ab142088 (Abcam). For the AKT inhibitor A-443654 (Abovchem), we 
injected mice s.c. twice per day as previously described156. 
3.4.7. Immunoblot 
0.2-1 × 106 CTLs were lysed in ice cold buffer containing 10 mM 
TrisHCl, 5 mM EDTA, 1% NP-40, 0.5% sodium deoxycholate, and 0.15 M 
NaCl. PTEN expression was assessed using a rabbit monoclonal antibody 
(clone: D4.3, Cell Signaling). Actin served as a loading control (clone: AC-15, 
Sigma). Images were collected on film or with the LICOR.  
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3.4.8. Nutrient depletion survival experiments 
For all experiments, media was obtained form the Memorial Sloan 
Kettering Cancer Center Media Preparation core facility. For the nutrient 
depletion experiments, RPMI was purchased without glucose, amino acids, or 
both. Fetal bovine serum (Sigma) or dialyzed fetal bovine serum (Sigma) was 
added to 10% (v/v). Human IL-2 was used at 30IU/mL. Mouse IL-7 (Life 
Technologies) was used at 1ng/mL and 10ng/mL. Cells were incubated in flat 
bottom 96 well plates at 37°C for 1 or 2 days. The samples were then washed 
into FACS buffer, stained with DAPI, and analyzed by flow cytometry. 
3.4.9. In vitro killing assays 
Cytotoxicity assays were performed using RMA-s cells that were 
stained with CellTrace Violet (Life Technologies) and then pulsed with varying 
concentrations of the SIINFEKL peptide for 1 hour. The cells were washed, 
counted and mixed with OT-1 CTLs at a 1:2 (effector:target) ratio in V bottom 
96 well plates in triplicate and incubated at 37°C for 3-4 hours. The cells were 
washed into FACS buffer and cell death was measured by flow cytometry. 
3.4.10. RNA isolation and RT-PCR 
RNA was generated from CTLs by performing a Trizol (Life 
Technologies) extraction with chloroform following standard protocols (Sigma). 
RNA was used to generate cDNA using qScript cDNA Supermix (Quanta 
Biosciences). For all reactions, GAPDH was used as a control. RT-PCR was 
performed using the primers: GAPDH-fw (5’- 
CTTTGTCAAGCTCATTTCCTGG -3’), GAPDH-rev (5’- 
TCTTGCTCAGTGTCCTTGC -3’), KLF2-fw (5’- 
GGCTAGATGCCTTGTGAGAAA -3’), KLF2-rev (5’- 
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TGCCATCGTCTCCCTTATAGA -3’), S1P1R-fw (5’- 
GGAGTATGTTTGTGGCTCTCTC -3’), S1PR1-rev (5’- 
TGCTCCCGTTGTGTAGTTTC -3’), CCR7-fw (5’- 
GGTTCCTGCCTCTCATGTATT -3’), and CCR7-rev (5’- 
GTAGGTATCCGTCATGGTCTTG -3’). 
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CHAPTER 4: CONCLUDING REMARKS  
In the present study, we examined T cell cytotoxicity and discovered an 
association between mechanical force and target cell killing. We examined 
force generation by T cells both in the plane of the IS and orthogonal to the IS. 
We found that shPTEN CTLs exerted larger pulling and pushing forces in both 
dimensions. We showed that these forces correlate with the increased 
cytotoxicity observed in PTEN deficient cells. We demonstrated a relationship 
between increased membrane tension on target cells and increased 
susceptibility to perforin. We proposed a model in which CTLs use the 
mechanical properties of the IS to increase membrane tension of target cells, 
thereby increasing the potency of LGs. We propose that the increased plasma 
membrane tension destabilizes the membrane by increasing the space 
between the phospholipids. Although our data supports this model, there are 
additional hypotheses for the mechanism of increased cytotoxicity, and some 
key questions related to our study remain unanswered. 
There are several alternative hypotheses for how force could contribute 
to perforin function that we did not address in our study. Force could increase 
the membrane susceptibility to perforin pore formation directly or it could alter 
the lipid composition of membrane, thereby enhancing its affinity for perforin. It 
is also possible that increased membrane tension could alter the topology of 
the membrane (e.g. by enforcing either convex or concave curvature), which 
could alter its susceptibility to perforin. Another possibility is that CTL-derived 
forces could physically damage target cells and that the target cell’s response 
to this damage might increase its susceptibility to perforin. These hypotheses 
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are not mutually exclusive with our other hypotheses and additional research 
is needed to address them. 
Although our studies implied that T cells alter target cell tension by 
exerting synaptic forces, we did not show this definitively. Technical limitations 
prevented us from examining plasma membrane tension in CTL-target cell 
conjugates. Current approaches to measure membrane tension rely on atomic 
force microscopy (AFM) or an optical trap. Unfortunately, the cantilever tip of 
an AFM is unable to access the target cell plasma membrane within the IS. 
The same is true for the optical trap approach. One way to circumvent these 
limitations, in principle, is by using genetically encoded tension sensors. There 
are fluorescent reporters that measure cortical membrane tension173, but these 
do not report the tension of the plasma membrane.  
Another way to measure membrane tension could be to use various 
tension sensitive ion channels, such as Piezo1 and Piezo2174. These ion 
channels have been shown to permit the flow of calcium ions in response to 
increased membrane tension174. We could over express these proteins on 
target cells and use intracellular calcium as a readout for membrane tension 
using a small molecule dye. We would then be able to monitor membrane 
tension during a CTL-target cell conjugate. This approach is intriguing but it 
would be unable to distinguish between alterations in global membrane 
tension versus localized membrane tension within the IS. Membrane tension 
has been shown to modify the activity of other pore forming proteins such as 
alamethicin175, but these proteins would have the same issues. Furthermore, it 
is conceivable that T cells could disrupt the integrity of the target cell 
membrane in a perforin independent manner within a conjugate. T cells 
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perform trogocytosis while in T cell-target cell conjugates so it is possible that 
T cells could disrupt the integrity of the plasma membrane. This could make 
changes in ion concentration an inaccurate readout for membrane tension.  
We would like to monitor membrane tension of T cells during the 
formation of conjugates and visualize it with degranulation using the pHluorin-
Lamp1 reporter. If this could be done at high resolution, it might be possible to 
examine whether a T cell releases lytic granules near regions of enhanced 
target cell membrane tension. It would also be interesting to measure 
membrane tension of the CTL plasma membrane to see whether it could play 
a role in protecting CTLs from perforin and granzyme. The precise mechanism 
of how CTLs protect themselves is unknown and membrane tension could 
play a role. Unfortunately, monitoring T cell membrane tension has the same 
associated challenges as monitoring it in target cells. 
Out efforts to apply PTEN deficiency to ACT have generated a number 
of interesting observations. We have demonstrated that modulating PI3K 
signaling by depleting PTEN does not improve tumor rejection in a 
transplantable melanoma model. In fact, we observed the opposite effect, and 
our subsequent studies highlighted the importance of trafficking and 
homeostatic proliferation for productive anti-tumor responses.   
In T cells, PI3K signaling drives cytoskeletal remodeling through 
Dock2/Rac and transcriptional and metabolic responses through AKT. We 
believe that this branched pathway structure explains why enhanced PI3K 
signaling leads to an increase in cytotoxicity (via Dock2/Rac) at the cost of 
reduced homeostatic proliferation and defects in migration (downstream of 
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AKT). By properly separating the two arms of the pathway, we might be able 
to increase cytotoxicity without diminishing homeostatic proliferation and 
migratory potential of the T cells. One way to do this is to only deplete PTEN 
upon TCR activation. Then the T cell will migrate properly to the tumor and, 
upon engagement of the TCR with pMHC, it will turn on expression of the 
shRNA to deplete PTEN. We previously tried expressing the PTEN shRNA 
under control of early T cell signaling promoters including nerve	  growth	  factor	  IB	  
(Nur77), IL-2, and NFAT. These constructs resulted in leaky expression of the 
shRNA and depletion of PTEN in the absence of TCR signaling. Hence, we 
were not able to fully explore the potential of this idea.  	  
Relying on homeostatic proliferation to generate anti-tumor responses 
might be a better approach than transferring more cells into a patient. 
Expanding CTLs in vitro over many generations can cause the cells to become 
dysfunctional and express exhaustion markers176. Dysfunctional CTLs respond 
poorly to antigen and produce reduced levels of cytokines upon restimulation. 
These cells also upregulate various inhibitory molecules including PD-1, 
VISTA, and others41,42,93. That being said, homeostatically expanded T cells 
are also known to express exhaustion markers and to exhibit some signs of 
dynsfunction177. These factors make the idea of using homeostatic expansion 
as an alternative to in vitro expansion less appealing. However, our work 
suggests that homeostatic proliferation as part of ACT is important and that it 
increases the anti-tumor response. 
Future studies will seek to find the optimal balance between CTL 
cytotoxicity, migration, and homeostatic proliferation when mounting an anti-
tumor immune response. In an anti-tumor response, cytotoxicity is obviously 
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important as it allows T cells to kill, but it seems unlikely that maximizing 
cytotoxicity will be an effective approach if it comes at the expense of 
homeostatic proliferation and migration. Indeed, our data imply that the 
opposite strategy may even be more fruitful.  If, for example, a T cell could be 
modified to significantly enhance homeostatic proliferation and tumor 
infiltration by a factor of 10 while reducing in vitro cytotoxicity by half, these 
cells might provide an enhanced anti-tumor effect while performing worse in 
cytotoxicity assays in vitro. Ideally, T cell proliferation and migration could be 
improved without altering cytotoxicity but reduced cytotoxicity in vitro could still 
lead to an improvement in ACT in vivo if other alterations compensated for this 
deficiency. 
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